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ABSTRACT:
A33 is a cell surface glycoprotein of colon epithelium with a long clinical history
as a target in antibody-based cancer therapy. Despite being present in normal colon,
radiolabeled antibodies against A33 are selectively retained by tumors at long time
points. Accordingly, we have studied the trafficking and kinetic properties of the antigen
to determine its promise in multi-step, pretargeted immunotherapy.
In vitro, the localization, mobility, and persistence of the antigen were
investigated, and this work has demonstrated that the antigen is both highly immobile and
extremely persistent, properties which may contribute to the prolonged retention of the
clinically administered antibodies, and their uncommon ability to penetrate solid tumors.
Secondly, because poor tissue penetration is a significant obstacle to the
development of successful antibody drugs for immunotherapy of solid tumors, we assess
the contribution of antigen density and turnover rate by evaluating the distance to which
antibodies penetrate spheroids when these properties are systematically varied. The
results agree well with the quantitative modeling predictions, and demonstrate that dosing
distal regions of tumors is best achieved by selecting slowly internalized targets that are
not expressed above the level necessary for recruiting a toxic dose of therapeutic.
Lastly, we describe the in vitro characteristics and report the promising in vivo
biodistribution of a multi-step tumor targeting therapy utilizing a novel bispecific
antibody which recognizes both the A33 antigen and a small molecule radiometal chelate.
Following these studies, several protein engineering techniques are presented.
First, a new method of conducting de novo protein engineering utilizing highly avid
magnetic beads is described, in which extremely weak interactions can be captured from
large library populations. Secondly, an in vitro assay which utilizes these highly avid
magnetic beads is used to score the clinical immunogenicity of therapeutic protein drugs
is presented. Finally, the use of sortase A as a means to generate fusion proteins post-
translationally is described. Taken together, this additional work demonstrates a
productive intersection of basic research and protein engineering methods.
Thesis Advisor: K. Dane Wittrup
Title: C.P. Dubbs Professor of Chemical Engineering & Biological Engineering
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Chapter 1: Background and Introduction
1.1 Abstract
Immunotherapy is a promising mode of cancer treatment which utilizes antibodies
to achieve the twin goals of systemic exposure and specific action. Here, we present a
case study of immunotherapy, in which we have selected a tumor antigen, examined its
clinical history and in vitro properties, used this information to determine an appropriate
targeting strategy, and investigated this altered protocol in a mouse model. This rational
approach to improving cancer therapy has lead to significant gains in in vivo studies.
1.2 Immunotherapy
Traditional cancer therapies are limited to highly specific treatments such as
surgery and external beam radiation, which have excellent ability to ablate primary
tumors; and systemic therapies such as chemotherapeutic drugs, which allow treatment of
metastatic and residual disease. However, chemotherapy has limited specificity, causing
significant toxicity to normal tissue, and surgery does not provide systemic exposure,
leaving a high probability of recurrence; whereas, the ideal treatment would offer
systemic exposure but possess highly specific action to eliminate the pathologic state of
cancer. When framing the design criteria for novel therapies in this way, it becomes
apparent that improved cancer therapies would mimic the function of the immune system,
which functions to differentiate self from sinister with a remarkable capacity to detect
and destroy pathogenic states.
However, when compared to the role of the immune system in combating
infectious disease, the problem with cancer is one of detection limits-how is
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differentiation of self from sinister possible when the sinister cells are of self origin, and
consequently bear much antigenic similarity to normal tissue. Interestingly, there is
evidence that our immune systems do have an existing capacity to provide tumor
surveillance in that individuals with autoimmune diseases have a lower incidence of
cancer, but when such individuals get cancer, their autoimmune disease tends to
subside-that is, individuals with more sensitive or reactive immune systems do a better
job at detecting cancer and destroying these misregulated self cells.
Though the bar for detection is set higher, it is perhaps similar to the immune
system's ability to detect the altered behavior of cells infected by a pathogen. Changes in
cellular behavior and expression patterns, even subtle changes in normal phenotypes can
function as molecular markers of disease. In this way, at this molecular level, each
transformative mutation allowing the altered growth profile of the cancer cell is a distinct
difference between tumor and normal tissue, and can function as a molecular marker of
cancer.
The premise behind immunotherapy is that these molecular markers of cancer can
be exploited as therapeutic targets. In fact, there are two general ways to use the immune
system to treat cancer. The first is antigen, or target driven, and includes cancer vaccine
strategies, which consist of training the immune system to recognize and eliminate
tumors. While promising, there are no approved therapies utilizing this cancer vaccine
strategy. The second type of immunotherapy is antibody driven, and relies on the
superior molecular recognition properties of antibodies to detect and treat cancer.
Antibodies have a long history as drugs dating back to the use of antiserums against
snake venoms, and antibody driven immunotherapy of cancer has been particularly
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fruitful. There are currently 9 FDA approved antibodies for cancer therapy-and many
other antibodies approved for the treatment of other diseases.
The differential success between antigen and antibody driven immunotherapy
may be partially explained by advances in antibody technology. These advances include:
hybridoma technology, which allows a single antibody specificity to be isolated and
produced-in stark contrast to the horse serum antibody products used previously; new
production systems that allow large yields of protein; and lastly, due to protein evolution
technologies such as yeast display, which allow the binding interaction between the
cancer target and the antibody to be engineered in vitro. The ability to evolve protein
drugs is particularly important because it means that therapy is not limited to use of
antibodies naturally generated by the immune system, but the binding properties of these
antibodies can be improved one-million-fold quite easily. Combined, these technologies
have made possible what Paul Ehrlich hoped some 100 years ago, that antibodies may be
used as "magic bullets" to specifically treat cancer. They may be administered
intravenously to achieve systemic circulation, but have specific action on tumors where
they bind their target antigen, decorate the surface of these cells, and interact with
immune system to trigger a cytotoxic response.
1.3 Mechanisms of antibody action
Interestingly, the ability to manipulate antibody properties in vitro has not only
allowed their binding, or detection functions to be improved, but also their destructive
properties. Naturally, antibodies act by two mechanisms. First, their conserved Fc
domains interact with complement proteins in the blood in what has been termed the
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complement cascade. Activation of complement factors results in formation of pores in
the cell membrane, resulting in cellular rupture. Second, the Fc interacts with receptors
on immune effector cells such as natural killer cells, which can likewise trigger
destruction of the antibody-coated cell. Much effort has gone into engineering Fc
variants that have improved abilities to initiate the complement cascade or activate
effector cells via improved interactions with activating Fcy receptors-.
However, antibodies can also utilize modes of action that are independent of
interactions with complement or effector cells. Such independence can be achieved by
utilizing an antibody which targets a cell surface marker and disrupts cellular signaling,
such as antibodies against some growth receptors do5-9. However, because this
mechanism requires the tumor marker to be necessary for growth, a simpler strategy is to
design the antibody to carry a toxin. Numerous approaches to incorporating a toxic
component to an antibody have been explored, including fusion to radionuclides,
nanoparticles that can be heat activated, toxic enzymes, enzymes which convert pro-
10-15drugs into active drug, and even DNA encoding cell-killing proteins
The appeal of these approaches is that they do not require activation of the
patient's own immune system in order to kill tumor cells because both targeting and toxic
functions are fully incorporated into a single molecule. While each of the different toxins
claims certain advantages over the others, enzyme fusions alter the pharmacokinetic
behavior of the antibody by increasing its size, the use of a foreign, generally bacterial
enzyme can lead to an immune response against the therapeutic, and some toxins require
not only internalization but also escape from the endosome to cause toxicity. Similarly,
fusion to nanoparticles, or liposomes encapsulating DNA increases size dramatically, and
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the specificity derived from the antibody may be dominated by passive size effects.
Radioactive antibodies, however, have a number of appealing attributes.
First, radiation is a well-established mode of cell killing. Secondly, radioactive
conjugation is a small perturbation to antibody size and structure, allowing the
pharmacokinetic behavior of the antibody to remain unaltered. Third, numerous
radioactive isotopes are available, ranging from alpha emitters with can achieve cell
killing with a single particle decay, to long range beta emitters which possess the ability
to kill cells at a distance by depositing their decay energy as much as a centimeter away,
allowing tumors to be fully irradiated without requiring that each cell be coated with
antibody. Given certain characteristics of the tumor microenvironment that disfavor the
penetration of antibody throughout solid tumors as will be discussed later, this cross-fire,
or bystander effect can be a significant advantage. Lastly, the specific localization of the
radioactive particle, whether intracellular or surface localized has less of an impact on
therapy. Accordingly, this work will focus on the use of radiation as the mode of cell
killing.
1.4 Limitations to antibody therapies
However, there are some drawbacks to antibody-based therapies. The first is the
strict requirement for a cancer-specific tumor antigen-a cell surface protein that is the
target of the antibody drug. Additionally, beyond simple tumor specificity, the cellular
target antigen must have the right profile in terms of other properties for the mode of
toxicity being used. For example, the cancer antigen must be expressed at a sufficient
level to recruit a toxic dose of therapeutic. For toxins that act intracellularly, it must be
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internalized at a sufficient rate, wheareas for some more complicated treatment regimens
such as multi-step therapies, it must remain surface accessible. Here, however, the
number of different toxins or radionuclides that can be used is an advantage, and allows
thoughtfully pairing of the mode of toxicity or decay properties given the properties of
the target antigen. This flexibility provides room for significant improvement in efficacy
given proper study of tumor susceptibility and target antigen properties. In fact, the first
line therapy for non-Hodgkin's lymphoma (NHL) is a radiolabeled antibody, which
performs significantly better than its non-radioactive variant-suggesting that in vitro
improvements to the natural binding (detection) and toxic (destruction) properties of
antibodies can allow substantial improvements in the clinic.
Unfortunately, there are a number of barriers to access in terms of localizing
antibody drugs to tumors. Of the antibody drugs currently approved for cancer, almost
all treat blood cancers while very few treat solid tumors, and those that are approved for
solid tumors have had disappointingly limited efficacy. Perhaps the most influential
barriers in localization are the transport phenomenon related to antibody access to solid
tumors. First, the antibody must extravasate from the blood through the vasculature. The
rate of vascular escape is highly unfavorable and can lead to a thousand fold decrease in
antibody concentration in solid tissue relative to the blood. For a directly radiolabeled
antibody this leads to a huge dose of radiation to the blood and bone marrow. Beyond
this barrier, the interstitial pressure in solid tumors is high, and the extracellular matrix is
dense, disfavoring flow through the tumor, and leaving diffusion down a concentration
gradient as the predominant mode of transport.
The effect of these barriers is strikingly apparent when the typical antibody
distribution within a solid tumor is observed. Generally, the antibody only penetrates the
tumor for a few cell layers-leaving whole regions of the tumor completely untargeted
and unexposed to antibody drug. Quantitative models of the relevant transport and
kinetic processes, which capture these effects have been developed and are highly useful
in terms of identifying the best ways to improve therapy 16-21. The success of radioactive
antibodies in treating NHL suggests that if we can identify and rationally engineer our
way around some of these limits we could generate successful therapies for solid tumors
as well. Short of these strategies, which include increasing vascular permeability, and
altering the affinity and valency of the antibodies used, selecting the right tumor target
and using an appropriate targeting strategy can circumvent some of these tumor
physiology-based limits.
1.5 Pre-targeted radioimmunotherapy
The recent success of several radioimmunotherapeutics has demonstrated proof of
principle for this type of targeted cancer therapy. Unfortunately, in many potential
applications, bone marrow toxicity limits therapy. In order to circumvent this toxicity, a
two-step strategy, known as pretargeted immunotherapy (PRIT) has been proposed, in
which the targeting construct and radionuclide are separated into two distinct dosing
steps. In this way, one preserves the specificity of antibody binding in tumor targeting,
but eliminates the toxic effects of long-lived, directly labeled antibodies. When compared
to single step therapies using directly labeled antibodies, PRIT has generally lead to
lower toxicity and better efficacy- 2 5 . However, the addition of a separate step constrains
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the desirable kinetic attributes of the cellular target in comparison with direct RIT,
immunotoxin therapy, or approaches relying on effector functions. In PRIT, the
competing interests of target saturation, clearance of unbound construct from circulation,
availability of the construct to chelated radionuclide, sufficient proximity to the nucleus
relative to decay pathlength, and the halflife of the radionuclide must all be taken into
consideration. This study seeks to determine if the A33 antigen, a member of the
immunoglobulin superfamily (IGSF) with homology to cell adhesion 26 and tight junction-
associated (TJ) proteins, possesses the properties particularly suited for PRIT.
1.6 A33 antigen as a tumor target
The A33 antigen is an abundant cell surface protein expressed in 95% of colon
tumors, but not in other organs27 . This restricted expression pattern led to interest in use
of the A33 antigen in radioimmunotherapy, and directly 125/1311 radiolabeled A33
antibodies were administered to patients with colon cancer in a series of phase I and II
clinical trials2833. The results of these trials were mixed from a therapeutic perspective,
as some patients developed an anti-antibody response34 , and there was dose-limiting bone
marrow toxicity. Alternatively, they were also quite promising in that they exhibited a
startlingly localized persistence of radiolabel. A33 was constitutively expressed in the
entire colon, and evenly throughout the entire crypt35. Provocatively, however, it was
found that after an initial period of time in which the therapeutic conjugate bound the
entire colon, after a period of a week, staining was present only in tumors28 and whole
body scans revealed labeling even 6 weeks after antibody administration30.
Significant work has gone into investigation of the tissue specific expression of
A33 35-37, whose promoter has now been used to drive colon-specific expression of
transgenes 38; the glycosylation pattern of the antigen 39,40, and its regulation by
PPARgamma4l. Despite homology to proteins of the tight junction, the cellular role of
A33 is unclear. Nonetheless, in addition to the human clinical studies cited already,
investigation into a number of novel formats including layer-by-layer polymer particles
and capsules, polyethylene glycol fusions, carboxypeptidase and cytosine deaminase
enzyme fusions, trivalent antibody fragments, and scFv 42-47 have been utilized in vitro
and in mouse models. Similarly, the use of numerous radiologic agents have been
investigated45'48 51, including lutetium, astatine, yttrium, bromine, and various iodine
isotopes.
1.7 Thesis overview
A33 is a cell surface glycoprotein of colon epithelium with homology to tight
junction-associated proteins of the immunoglobulin superfamily, including CAR and
JAM. Its restricted tissue localization and high level of expression have led to its use as a
target in colon cancer immunotherapy. Although the antigen is also present in normal
colon, radiolabeled antibodies against A33 are selectively retained by tumors in the gut as
well as in metastatic lesions for as long as 6 weeks 0 . Accordingly, we have studied the
trafficking and kinetic properties of the antigen to determine its promise in two-step,
pretargeted therapies, and have considered this target at 3 different levels: at cells
cultured in vitro-allowing study of the basic biology of A33; at spheroids, an in vitro
tumor models-allowing higher order study of antibody diffusion and binding; and in
vivo in a mouse tumor model where we can fully explore this 2 step strategy.
In vitro, the localization, mobility, and persistence of the antigen were
investigated, and this work has demonstrated that the antigen is both highly immobile and
extremely persistent-retaining its surface localization for a turnover halflife of greater
than 2 days. In order to explain these unusual properties, we explored the possibility that
A33 is a component of the tight junction. The simple property of surface persistence,
described here, may contribute to the prolonged retention of the clinically administered
antibodies, and their uncommon ability to penetrate solid tumorss2
Poor tissue penetration is a significant obstacle to the development of successful
antibody drugs for immunotherapy of solid tumors, and diverse alterations to the
properties of antibody drugs have been made to improve penetration and homogeneity of
exposure. However, in addition to properties of the antibody drug, mathematical models
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of antibody transport17 5 3 predict that the antigen expression level and turnover rate
significantly influence penetration. As intrinsic antigen properties are likely to be
difficult to modify, they may set inherent limits to penetration. Accordingly, in our
spheroid studies we assess their contribution by evaluating the distance to which
antibodies penetrate spheroids when these antigen properties are systematically varied.
Additionally, the penetration profiles of antibodies against CEA and A33, two targets of
clinical interest, are compared. The results agree well with the quantitative predictions of
the model, and demonstrate that dosing distal regions of tumors is best achieved by
selecting slowly internalized targets that are not expressed above the level necessary for
recruiting a toxic dose of therapeutic. Each antibody-bound antigen molecule that is
turned over or present in excess incurs a real cost in terms of penetration depth-a
54limiting factor in the development of effective therapies for treating solid tumors
Lastly, we describe the in vitro characterization and in vivo biodistribution of a
multi-step tumor targeting therapy utilizing a novel bispecific antibody which recognizes
both the A33 antigen and a small molecule radiometal chelate. This bispecific antibody
consists of a typical IgG molecule with an additional scFv domain fused to the C
terminus of the IgG light chain, generating a tetravalent molecule capable of recognizing
2 copies of the A33 tumor antigen, and 2 small molecule radiometal chelates. Following
in vitro testing, the A33 bispecific was administered to mice bearing SW1222 xenograft
tumors and its biodistribution was determined. Subsequent preliminary experiments have
characterized the effect of a clearing step utilized to block and eliminate the remaining
blood pool fraction of bispecific prior to administration of a radioactive DOTA chelate
and determinations of its biodistribution and tumor uptake. These studies strongly
support further investigation of the A33 antigen as a target in multi-step immunotherapy.
Following these studies of the A33 antigen in terms of its basic cell biology, its
characteristics in a spheroid tumor model, and its use in a multistep strategy in a mouse
xenograft model, several protein engineering techniques are presented. First, a new
method of conducting de novo protein engineering utilizing highly avid magnetic beads is
described, in which even very weak interactions can be captured from large library
populations". Secondly, an in vitro assay which utilizes these highly avid magnetic
beads is used to predict the clinical immunogenicity of therapeutic protein drugs is
presented. And finally, the use of sortase A as a means to generate fusion proteins post-
translationally is described. Taken together, this additional work demonstrates a
productive intersection of basic research and protein engineering methods.
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Chapter 2: A33 antigen displays persistent surface expression
2.1 Abstract
A33 is a cell surface glycoprotein of colon epithelium with homology to tight
junction-associated proteins of the immunoglobulin superfamily, including CAR and
JAM. Its restricted tissue localization and high level of expression have led to its use as a
target in colon cancer immunotherapy. Although the antigen is also present in normal
colon, radiolabeled antibodies against A33 are selectively retained by tumors in the gut as
well as in metastatic lesions for as long as 6 weeks1 . Accordingly, we have studied the
trafficking and kinetic properties of the antigen to determine its promise in two-step,
pretargeted therapies. The localization, mobility, and persistence of the antigen were
investigated, and this work has demonstrated that the antigen is both highly immobile and
extremely persistent-retaining its surface localization for a turnover halflife of greater
than 2 days. In order to explain these unusual properties, we explored the possibility that
A33 is a component of the tight junction. The simple property of surface persistence,
described here, may contribute to the prolonged retention of the clinically administered
antibodies, and their uncommon ability to penetrate solid tumors.
Major portions of this chapter were previously published in:
Ackerman ME, Chalouni C, Schmidt MM, Raman VV, Ritter G, Old LJ, Mellman I, Wittrup KD. "A33
antigen displays persistent surface expression" Cancer Immunol Immunother. 2008 Jul;57(7)1017-27.
2.2 Background
The recent success of several radioimmunotherapeutics has demonstrated proof of
principle for this type of targeted cancer therapy2. Unfortunately, in many potential
applications, bone marrow toxicity limits therapy. In order to circumvent this toxicity, a
two-step strategy, known as pretargeted immunotherapy (PRIT) has been proposed, in
which the targeting construct and radionuclide are separated into two distinct dosing
steps. In this way, one preserves the specificity of antibody binding in tumor targeting,
but eliminates the toxic effects of long-lived directly labeled antibodies. When compared
to single step therapies using directly labeled antibodies, PRIT has generally lead to lower
toxicity and better efficacy 3-5. However, the addition of a separate step constrains the
desirable kinetic attributes of the cellular target in comparison with direct RIT,
immunotoxin therapy, or approaches relying on effector functions. In PRIT, the
competing interests of target saturation, clearance of unbound construct from the
circulation, availability of the construct to chelated radionuclide, sufficient proximity to
the nucleus relative to decay pathlength, and the halflife of the radionuclide must all be
taken into consideration. This study seeks to determine if the A33 antigen, a member of
the immunoglobulin superfamily (IGSF) with homology to cell adhesion 6 and tight
junction-associated (TJ) proteins, possesses the properties particularly suited for PRIT.
The A33 antigen is an abundant cell surface protein expressed in 95% of colon
tumors, but not in other organs 7. This restricted expression pattern led to interest in use
of the A33 antigen in RIT, and directly 125113'1 radiolabeled A33 antibodies were
administered to patients with colon cancer in a series of phase I and II clinical trialsi,812
The results of these trials were mixed from a therapeutic perspective, as some patients
developed an anti-antibody response 3 , and there was dose-limiting bone marrow toxicity.
Alternately, they were also quite promising in that they exhibited a startlingly localized
persistence of radiolabel. A33 was constitutively expressed in the entire colon, and
evenly throughout the entire crypt 1. Provocatively, however, it was found that after an
initial period of time in which the therapeutic conjugate bound the entire colon, after a
period of a week, staining was present only in tumors8 and whole body scans revealed
labeling even 6 weeks after antibody administration .
Distinguishing self from target cells poses a particular problem in cancer, in which
the tumor cells are of self-origin and consequently share much antigenic similarity with
the tissue of their origin. RIT rests on the premise that there are surface antigens with
differential expression in tumors. Despite failing to fulfill this basic premise, and
consequent dosing of the entire colon with radioactivity in A33 antigen RIT studies, dose-
limiting toxicities were not gastrointestinal. However, the lack of gastrointestinal toxicity
could be attributed to the relatively small dose of radiation to both tumor and normal
colon in comparison to the dose absorbed by the blood, which was the limiting toxicity.
Under conditions in which there was a therapeutic effect on tumor cells, it is likely that
the expression on normal cells would present a toxicity problem. Accordingly, the
presumptive ceiling imposed by normal tissue expression, and the tumor-specific staining
observed after a week, provoke considerable interest in the study of A33 as a two-step
immunotherapy target.
Several possible explanations have been advanced as to how tumor specificity
occurs for A33 antibodies, including differential accessibility or endocytosis between
normal and cancerous tissue. However, the simplest notion is that specificity results from
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normal shedding of the colonic epithelium. As this process of migration and sloughing
occurs over the course of several days, this theory is consistent with the clinical data.
Regardless of the mechanism by which tumor-specificity is gained, in order to be
a useful target in PRIT, the antibody specifically localized to tumors after one week must
be retained on the tumor cell surface-available to bind a radionuclide construct.
Therefore, we undertook a study to determine the trafficking and persistence of the A33
antigen in cultured colon tumor cell lines, as well as some preliminary work to understand
the etiology of this unique in vivo persistence.
2.3 Materials and Methods
Cell Culture
The A33-expressing cell lines LS174T, LIM1215, COL0205, and SW1222 cells were
grown in advanced MEM supplemented with L-glutamine and 10% FBS (Gibco). Where
appropriate, cells were fixed and permeabilized with BD cytofix and cytoperm (BD
Biosciences) according to the manufacturer's instructions. Latrunculin B (Sigma) and
nocodazole (Sigma) were dissolved in DMSO and added to culture for final
concentrations of 100 nM and 50 gM, respectively. EGTA was directly dissolved in
culture media for a final concentration of 25 mM.
Fluorescent Labeling of Cells
The mouse anti-A33 antibody m1O0.310 was conjugated to Alexa*488 or fluorescein
according to the manufacturer's instructions (Molecular Probes A-20181, F-6433), and
goat anti-mouse PE was used as a secondary (Sigma). Anti-CEA shMFE was likewise
conjugated to Alexa*594 (Molecular Probes A30008). For colocalization experiments,
LIM1215 cells were permeabilized-fixed with methanol, -20*C, for 5 min and then
stained with either rabbit anti-human occludin (Zymed), or mouse anti-human ZO-1
(Zymed). They were detected by Cy3-conjugated donkey anti-rabbit and anti-mouse
antibodies, respectively (Jackson immunoresearch Laboratories). Actin was labeled with
Alexa*546-conjugated phalloidin (Molecular Probes).
Vybrant DiI (Molecular Probes) was used to label bulk membrane for photobleaching
experiments. For DiI labeling, the media above the monolayer was replaced with 300
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mM sucrose in PBS, and then 2 gi of the DiI label was slowly added to the sucrose
solution above the monolayer.
Fluorescence Microscopy
Cells were grown on coverslip-bottomed dishes (Mattek), labeled as previously
described, and imaged on a Deltavision deconvolution microscope with 1.4 NA oil lens at
1 00x magnification and deconvolved and analyzed using the SoftWorx application.
Colocalization study images were aquired using a confocal LSM510 Zeiss microscope
equipped with an oil immersion plan apochromatic 1 00x lens, NA 1.4.
Flow cytometric Internalization Assay1 5
A suspension of 4x10 6 cells/ml was labeled with m100.310 Alexa*488 in media on ice
for 1 hr at 100 ng/ml. C0 2-independent media (Gibco) was then exchanged and cultures
were diluted to 4x10s cells/ml and set in a 37'C shaker for the course of the experiment.
At each timepoint, 1 ml aliquots were taken, washed once with 0.5 ml PBS 0.1% BSA,
and labeled with 100 pl of 2:100 dilution of anti-mouse PE (Sigma) on ice for 15 min,
before analysis on a Beckman Coulter XL-4 flow cytometer. The average fluorescence
signals of primary and secondary antibodies were then plotted against time. Secondary-
only and 4*C controls were maintained.
Transepithelial Electrical Resistance Measurements
80,000 SW1222 cells were plated on a transwell insert (Coming 3470). One day after
plating, lI of anti-FLAG antibody (Sigma) and huA33 antibody at lmg/ml were added
to both apical and basolateral chambers. Resistance measurements were taken daily with
a millcell-ERS (Millipore) after equilibration of the plate for an hour at room
temperature.
Fluorescence Recovery after Photobleaching
LS174T cells were labeled with either fluoresceinated m100.310 or the membrane dye
DiI as described previously. Bleaches were performed on a Zeiss LSM 510 confocal
microscope with a 1.4 NA oil lens at 67x magnification on a heated stage. Sections of
membrane were bleached with full laser power on all channels for 50 to100 iterations,
resulting in bleaches of between 20 and 80% of initial fluorescence. Fluorescence
intensity in the bleach region was recorded and then adjusted to correct for background
bleaching due to repetitive imaging over the course of the experiment. Appropriate
controls were performed in order to ensure that bleaching was non-reversible. Data
presented is the average of a minimum of 6 experiments. Relative diffusivities were then
calculated 6 18
Biotinylation Turnover Assay19
The biotinylation turnover assay was adapted from a protocol designed to measure
endocytosis and recycling rates2 0 . Briefly, cell surface proteins were pulse biotinylated by
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incubation for 1 hour in 1 ml of ice cold PBS containing freshly dissolved NHS-SS-
Biotin (Pierce 21217). Biotinylation media was replaced with 100 mM Tris to quench
unreacted biotin for 5 min at 4'C, followed by replacement with culture media. At each
timepoint, media was removed and cells were incubated in 1 ml lysis buffer for 10
minutes. They were washed off the plate and set on ice in a microfuge tube for another
10 minutes after vortexing briefly. Samples were then spun at 12,000 rpm for 15 min to
clear the lysate. Supernatant was removed and then frozen. When the timecourse was
complete, samples were rotated with 100 pl streptavidin resin beads (Pierce 53114)
overnight at 4*C. Beads were then washed and biotinylated proteins were cleaved off the
beads by incubation in 75 p1 of 100 mM DTT in PBS at 370 C for 1 hour, mixing every 15
minutes. Samples were mixed with loading buffer and run on a 4-12% bis-tris gel
(Invitrogen) and run and transferred onto nitrocellulose according the manufacturer's
instructions. Nitrocellulose was blocked and blotted as previously described to detect
denatured A33 antigen.
2.4 Results
2.4.1 Homeostatic and kinetic localization of A33 antigen
A panel of A33-expressing colon tumor cell lines were fixed, permeabilized, and
stained to detect A33 (Figure 2.4.1a). Surprisingly, and in contrast with earlier reports
which used acid washes to demonstrate the internalization of 40% of the antigen 2 , there
was very little evidence of intracellular staining in most of the lines tested, suggesting
there may be little, if any endocytosis of the A33 antigen. LIM1215 cells were an
exception and had clear intracellular accumulation. This cell line may be representative
of a subclass of colonic crypt cells located at the extreme tip of the villus, which are about
to be shed (C. Chalouni, unpublished). This surprising result was confirmed and
quantified for a larger population of cells using a kinetic flow cytometry assayi5 capable
of following the course of antigen internalization (Figure 2.4.1b). Suspended cells were
A33-labeled on ice, washed, and incubated in media at 37*C. At various times, aliquots
were removed and labeled with PE-conjugated anti-mouse secondary, such that primary
signal corresponds to total antigen, and secondary signal to the fraction of antigen that
remains surface accessible. Average fluorescence intensities were standardized to time
zero and graphed over time. In most cell lines, the fractional decline in primary and
secondary signals was roughly equal, indicating that the bulk of the primary-labeled
antigen remained on the cell surface. In each experiment, primary signal was seen to
decrease, which is likely due to dissociation of the primary antibody, as the antigen itself
is not shed 8. Thus, with the exception of LIM1215, there appeared to be little
endocytosis in these cells (Figure 2.4.1b), consistent with the small amount of A33
residing in intracellular compartments (Figure 2.4.1 a).
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Figure 2.4.1: Distribution of antibody-bound A33 antigen. (a) Cultured colon tumor
epithelial cells contain little intracellular A33 antigen. Each of 4 cell lines were grown
on coverslips, fixed, permeabilized, and A33 antigen was labeled with the monoclonal
antibody mlOO.310*Alexa 488. Internal pools of antigen were seen only in L1M41215
cells. Bar represents 5 pM. (b) Antibody-bound A33 antigen shows persistent
surface localization in a flow cytometric assay of dynamic internalization kinetics.
Suspended cells were A33-labeled at 0*C and then incubated at 37*C, allowing labeled
antigen to be internalized. After shifting cultures to 37*C, aliquots were removed and
labeled with anti-mouse PE and analyzed flow cytometry in order to determine the
fraction of labeled A33 that remained surface accessible over time. The level of surface-
accessible A33 did not fall significantly below the level of total A33, indicating little
internalization of the A33 antigen in all cell lines tested except LIM1215. The decrease
in total A33 signal is likely due to dissociation of the primary antibody, as the antigen is
not shed.
2.4.2 Colocalization Profile
The lack of significant internalization of the antigen in several tumor cell lines
raised questions concerning the mechanism of this persistence at the surface. Given its
homology to several tight junction-associated proteins and cell adhesion molecules
(CAMs), a series of colocalization studies were performed (Figure 2.4.2). Despite
differing substantially from the other lines tested, LIM1215 cells were used for this work,
as they were potentially more discriminatory due to their internal reservoir of antigen.
Indeed, in immunofluorescence images of LIM1215 cells, A33 was shown to partially
colocalize with occludin (a), ZO-1 (b), and actin (c), not only at the plasma membrane,
but also in a few intracellular vesicles.
Tight Junction Protein
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c
Figure 2.4.2: Colocalization profile of A33 antigen. Tight junction proteins are false-
colored in red, and A33 antigen in green. (a) A33 partially colocalizes with the tight
junction protein occludin. Immunofluorescence image of LIM1215 cells showing
colocalization of A33 antigen and occludin. (b) A33 partially colocalizes with the actin-
binding, tight junction-associated protein, ZO-1. Immunofluorescence image of
LIM1215 cells showing colocalization of A33 antigen and ZO-1. (c) A33 partially
colocalizes with the cytoskeleton. Immunofluorescence image of LIM1215 cells
showing colocalization of A33 antigen and actin.
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2.4.3 Investigation of A33 as a tight junction-associated protein
Next, based on its homology to and colocalization with various TJ proteins, we
determined whether A33 is trafficked in a manner similar to other TJ proteins. A number
of physiological changes and signaling molecules are capable of altering the composition
or disrupting the localization of the TJ2 3-26. The best known of these disruption methods
consists of a calcium switch from normal media concentrations to a low calcium
environment, either by use of calcium-free media, or by chelation, resulting in
endocytosis of the TJ.
Indeed, when A33-labeled LS174T cells were treated with 25 mM EGTA, a
fraction of the surface A33 was endocytosed into intracellular compartments (Figure
2.4.3a) similar to those observed for TJ proteins such as JAM-1, occludin, and ZO-1, the
adherens junction molecules p-catenin and E-cadherin . As the various components of
the TJ can be sorted into different compartments upon internalization, we also sought to
determine the fate of endocytosed antigen. The internalization assay was modified such
that LS174T cells were first A33-labeled and then internalization was triggered by a
calcium switch. Low calcium media was then replaced with fresh, calcium-containing
media (washout), and recycled antigen was detected by binding of a secondary antibody
(Figure 2.4.3b closed squares). The clear increase in secondary signal indicates that
internalized antigen was able to return to the surface. In order to distinguish the relative
contributions of resurfacing and possible new synthesis following the calcium switch,
samples were also re-labeled with primary (open circles) following the incubation with
secondary antibody. Recycling accounted for the bulk of overall signal increase, as
opposed to additional primary labeling, which includes both new synthesis as well as
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replacement of primary label that may have dissociated during the course of the
experiment.
Another behavior common to various IGSF proteins is a role in adhesion and
subsequent establishment of barrier function-many A33 homologs participate in dimeric
interactions involved in securing cell-cell contacts 28-31. A number of viruses bind to IGSF
proteins, even producing proteins that interfere with epithelial integrity by blocking these
dimeric interactions32 . We therefore investigated the ability of the clinical anti-A33
antibody to influence monolayer integrity. One day after plating on a transwell insert,
SW1222 cells were treated with either huA33 antibody or mouse anti-FLAG antibody as
a control. In the presence of A33 antibody, the monolayer did not fully tighten, as
evidenced by a decrease in electrical resistance, indicating a greater degree of leakiness of
the tight junctions (Figure 2.4.3c). This increased permeability not only connects A33 to
other tight junction proteins and IGSF's, it implies a possible functional role in adhesion.
Interestingly, when A33 antibodies were applied to fully formed monolayers, they were
unable to increase permeability (data not shown), indicating that they lack the ability to
actively pry open sealed junctions. This discrepant behavior may indicate that there is
differential access to antigen between normal colon and tumors, which are known to
possess disordered and leaky tight junctions 33,34.
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Figure 2.4.3: Investigation of A33 as a tight junction-associated protein. (a) Calcium
chelation triggers A33 internalization. LS174T cells were labeled with
m1O0.310*Alexa 488, and culture media was treated with 25 mM EGTA to chelate
calcium. At 2 hours, there were clear intracellular pools of antigen, a phenomenon
common to junction-associated proteins. (b) Replacement of calcium restores A33
surface localization. When EGTA is washed out, previously labeled A33 returns to the
surface. Cell aliquots were labeled with m1O0.310*Alexa 488 and then treated with
EGTA for 2 hours. Following media replacement, aliquots were removed and labeled
with a secondary-PE conjugate, and then again with m100.310*Alexa 488, and subjected
to flow cytometry. (c) Anti-A33 antibody decreases monolayer integrity. SW1222
cells were grown on transwell inserts, treated with antibodies 1 day after plating, and
transepithelial electrical resistance was measured across the monolayer.
2.4.4 Determination of the role of cytoskeleton in A33 localization
Thus far, we have demonstrated that A33 antigen is partially colocalized with
various TJ components, is internalized upon calcium switch, and antibodies to A33 can
influence monolayer resistance. These results suggest a role for A33 at the TJ-an
interesting possibility given the disorder of the TJ in cancer 33,35 ,36 and some of the
proposed mechanisms of how A33 antibodies may gain tumor specific localization
despite expression throughout the colon. However, from a tumor-targeting perspective,
these results are secondary to the unusual persistence of radiolabel in clinical patients,
and the lack of internalization observed in cultured cells (Figure 2.4.1). In fact, the
results of the internalization assay hint at surface persistence that is longer lived than bulk
membrane and accompanying proteins. In order to avoid capture and degradation during
normal membrane turnover, we next supposed that there might be a tether actively
stabilizing A33. Due to it's colocalization with actin, and the actin-TJ linking protein
ZO-1, the cytoskeleton was clearly implicated. Additionally, the cytoskeleton has been
shown to regulate junction assembly and remodeling. Accordingly, actin and
microtubules were disrupted by treatment with either latrunulin (Figure 2.4.4a) or
nocodazole (Figure 2.4.4b). When A33-labeled cells were treated with these
cytoskeleton-disrupting drugs, the antigen was internalized in a manner similar to the
calcium switch-indicating that persistent surface localization requires intact
cytoskeleton. Additionally, following a calcium switch, LS174T cells were washed into
either normal media or media containing EGTA, nocodazole, or latrunculin, and at
various timepoints aliquots were removed, A33 labeled, and analyzed by flow cytometry
(Figure 2.4.4c). When EGTA was washed out and no drugs were washed in, the surface
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localization of A33 was restored. However, restoration was prevented by disruption of
the cytoskeleton.
Since many TJ proteins interact with the cytoskeleton and ZO-1 through a series
of well-characterized binding domains, we looked for motifs within the A33 intracellular
38domain, which has been described as unusually acidic . Upon closer inspection, a short
region with high homology to occludin was found (Figure 2.4.4d). Initially, this region of
occludin was found to be required for TJ/membrane localization 3. When the crystal
structure of occludin was solved, it was found that this region acts as a hinge between two
positively charged, acidic domains that are required for binding to ZO-140 . Despite being
otherwise non-homologous, the similarity between its intracellular domain and that of
A33 are striking and point toward the possibility that they may have a common set of
interactions with cytosolic proteins-most notably with the actin cytoskeleton, possibly
through ZO-1.
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Figure 2.4.4: Determination of the role of cytoskeleton in A33 localization. (a) Effect
of disrupting actin on antigen distribution. Immunofluorescence images of A33-
labeled LS 174T cells after treatment with 100 nM latrunculin B for 2 hours demonstrates
internalization. (b) Effect of disrupting microtubules on antigen distribution.
Immunofluorescence images of A33-labeled LS174T cells after treatment with 50 sM
nocodazole for 2 hours demonstrates internalization. (c) Disruption of the cytoskeleton
prevents recovery of surface-expressed A33. LS174T cells were labeled and then
incubated with EGTA. Following internalization, media was exchanged with either fresh
media (washout), or fresh media containing latrunculin, nocodazole, or EGTA (continued
EGTA). Surface localization was restored only in cells with intact cytoskeleton and
normal calcium levels. (d) Possible functional homology between A33 and occludin
intracellular domains. A33 and occludin share a highly acidic intracellular region and a
negatively charged hinge found to be important for TJ localization. Hydrophobicity plot
of A33 antigen, detailing the hinge region with high homology to occludin.
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2.4.5 Determination of the mobility and persistence of A33
As another means of assessing whether the A33 antigen is tethered on the
membrane or part of a large protein complex such as the TJ, a series of photobleaching
experiments was performed, in which the cell membrane was bleached at cell-cell
junctions, and the recovery of either fluorescein-conjugated A33 antibody or the
membrane dye DiI was followed. The fluorescence of the membrane dye DiI had an
almost complete recovery, while only 10% of A33 fluorescence was seen to recover over
the course of one minute (Figure 2.4.5a). When observed over a longer period of time,
A33 recovery was quite slow, and indicated that more than half of the antigen is
immobile (Figure 2.4.5b). This dramatic surface immobility corresponds quite well to
other tight junction proteins which have been studied in both cultured cells and live
drosophila embryos 41,42.
The bleach geometry used prevents reporting of an accurate diffusivity value, as
diffusivity is highly dependent on the area of the bleach region, which could not be
precisely determined. However, since bleach areas were similar for both A33 and DiI,
relative diffusivities can be reported. Excluding the immobile fraction, the diffusivity of
A33 was 2.5-3 orders of magnitude slower than that of DiI. As a second point of
comparison, DiI recovery was compared to recovery of a CEACAMI-egpf fusion
protein 43 in MCF-7 cells, which were a kind gift from Dr. John Shively (data not shown).
CEACAM1-egfp is known to reside in lipid rafts and also associate with actin through its
short cytoplasmic domain44'45. Using the same bleach methodology, the diffusivity of
CEACAMi was found to be on the same order of magnitude as DiI.
As there was no significant difference between the recovery of A33 at regions of
cell-cell contact and at regions of the membrane not associated with other cells (data not
shown), this stability must not depend on trans interactions between cells at the TJ, and
points toward either the incorporation of A33 antigen into a larger protein complex which
is highly stabilized, or a more direct interaction with static regions of the cytoskeleton.
Regardless of mechanism, an interaction with the cytoskeleton is consistent with our
colocalization observations, homology, and the data demonstrating that the cytoskeleton
is necessary for localization.
Additionally, since the persistence of label in clinical patients is the key feature of
this antigen, we next determined the turnover halflife of antigen in cultured LS174T
monolayers (Figure 2.4.5c). Monolayers were pulse-biotinylated and at various
timepoints total protein was extracted. Biotinylated proteins were pulled down by
incubating the lysate with streptavidin resin, and then cleaved from the resin by reduction
of a disulfide bond. The resulting samples were run on an SDS-PAGE gel, transferred to
nitrocellulose, and blotted to detect A33. Band intensities were quantified and fitted to an
exponential decay. In this manner, the halflife of A33 was found to be 56 hours. With a
halflife of over 2 days, the A33 antigen is highly persistent relative to typical membrane
proteins turnover times. This long halflife is certainly partially responsible for the
sustained persistence of the therapeutic antibody to A33 in patients. Most significantly,
this long halflife provides a strong motivation for further clinical study of the antigen as a
target in PRIT.
Lastly, as there are a number of cell surface antigens with promise as targets in
PRIT, we also directly compared A33 with what is perhaps the best studied of these
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antigens. Carcinoembryonic antigen (CEA) is a cell surface antigen that is frequently
expressed at high levels at the apical surface of epithelial cells, and in a nonpolarized
surface pattern in colon tumors46 . Numerous studies have been performed targeting this
well-characterized protein. As accessibility to chelated radionuclide is a key requirement
for successful PRIT, we sought to compare the accessibility of A33 with CEA.
Accordingly, cells were labeled with both an anti-A33 antibody (mlOO.310 Alexa*488)
and an anti-CEA scFv (shMFE Alexa*594), and incubated at 37*C for 2 hours prior to
imaging. Intriguingly, after as short a period of 2 hours, there is significant
internalization of CEA, while A33 remains stably located at the cell surface, available to
bind the radionuclide construct (Figure 2.4.5d).
Taken together, these results demonstrate that the A33 antigen is a highly
persistent, largely immobile, surface-localized protein. These findings help explain the
unusual persistence of tumor associated anti-A33 antibodies in clinical trials, and indicate
that the A33 antigen may have unique promise as a target in PRIT.
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Figure 2.4.5: Determination of the mobility and persistence of antibody-bound A33.
(a) Over the course of 1 minute, bleached plasma membrane has a near full recovery
of fluorescence while very little A33 recovers. Fraction of fluorescence recovered over
time for bleached m100.310 antibody bound to A33 and the plasma membrane marker
DiI. (N=8, LS174T cells). (b) Even over much longer time scales, antibody-bound
A33 fluorescence recovery is slow and incomplete. 35-minute time course of antibody
bound to A33 after photobleaching. (N=6, LS174T cells). (c) The A33 antigen is
persistent, having a surface expression halflife of 56 hours in cultured monolayers.
Cell surface proteins of cultured LS174T cells were pulse-biotinylated, extracted, and
pulled down with streptavidin beads. The precipitated proteins were reduced off the
beads, subjected to gel electrophoresis and blotted to detect A33 antigen. Signal intensity
of two data sets is plotted against time post-biotinylation, and fit to an exponential decay.
(d) While other immunotherapy targets are internalized, A33 antigen remains on
the surface. LS174T cells were labeled with both mlO0.310*Alexa 488 and anti-CEA
shMFE*594 for 2 hours at 37*C before imaging on a deconvolution microscope.
.. .... ..... ....... ........ ..   ........ ....................
2.5 Discussion
A33 is a highly persistent surface-localized antigen. While the antigen is not
cancer-specific, antibodies against A33 gain tumor specificity over the course of a week,
possibly as the normal colon epithelium is shed. Most tumor cell lines tested showed
little to no internalization of the antigen, both by immunofluorescent imaging of
permeabilized cells, and in a flow cytometric internalization assay which monitored
accessibility to a secondary antibody. While initially surprising, as there had been reports
that the antigen was largely internalized, this result is consistent with
immunofluorescence images of resected colon tissue, in which the steady-state
distribution of antigen is entirely on the cellular surface, with the possible exception of
cells at the very tip of the crypt which are about to be shed (C. Chalouni, unpublished).
This phenotype may be reflected by the LIM1215 cell line, which unlike the rest of the
lines tested, did internalize the antigen.
As a member of the immunoglobulin superfamily (IGSF) of proteins, which
comprises a full 2% of the genome, A33 is a member of the largest class of mammalian
proteins. Their basic extracellular structure consists of domains resembling the IgG fold,
and they have notable diversity in their intracellular domains. Striking features of the
A33 intracellular domain include a quadruple cysteine repeat followed by a highly acidic
sequence. Its closest homologs include the coxsackie adenovirus receptor (CAR)47,
cortical thymocyte receptor (CTX) 47, endothelial cell adhesion molecule (ESAM),
junction adhesion molecules 1-3 (JAM) 48, and CEA-related cell adhesion molecules
(CEACAMs) 49. Many of these homologs have been implicated in cell-cell adhesion, and
some are localized to regions of cell-cell contact or to the tight junction more specifically.
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They typically participate in dimeric interactions, and many also serve as attachment
points for various intestinal viruses.
Here, we have described experiments that reveal some of the molecular properties
of the A33 antigen. Taken together, this work demonstrates the persistent, immobile, and
stable surface expression of A33-properties which may result from a link to the
cytoskeleton through a complex of tight junction components. Additionally, these
properties may be the source of the A33 antigen's uniquely promising profile in clinical
trials.
In the clinic, antibodies to A33 exhibit two distinctive properties. First, they
remain tumor-localized for weeks. In some cases, persistent tumor localization is due to
the residualizing properties of metal radionuclides. However, the A33 clinical trials have
utilized radioactive iodine. Questions remain as to how these antibodies were able to
persist-whether they were sequestered and stored along some trafficking route, or
whether they simply remained bound to surface-localized antigen. Our studies here are
consistent with the notion that the A33 antigen is surface-stabilized through a link to the
cytoskeleton or as a part of a stable protein complex or membrane microdomain that
allows the antigen to escape bulk membrane endocytosis and subsequent trafficking and
endocytosis. The turnover halflife of greater than 2 days found here also likely
underestimates the true turnover time in vivo. Over the course of the protocol used here,
the cultures become overpopulated and some cells may respond by undergoing apoptosis,
resulting in an artificially shorter halflife. Additionally, as mentioned previously,
intracellular A33 staining is not seen in sections of human colon, except at the very tip of
the villus, in cells that are proximal to being shed (C. Chalouni, unpublished). This data
indicates that the simple explanation of persistence due to a lack of antigen turnover may
be correct.
Secondly, and more significantly, antibodies to A33 were found to penetrate solid
tumors". The ability to penetrate solid tumors has proven to be a significant obstacle in
RIT. To date, few successful RIT therapeutics target solid tumors. This failure is due to
what are generally the conflicting goals of avoiding bone marrow toxicity while at the
same time penetrating and thoroughly dosing tumor tissue. As a means to evade this
toxicity at the same time as increasing penetration, manipulations of targeting construct
size have been studied extensively. While these alterations do have the desired effect on
clearance parameters, thorough tumor penetration has still proven an elusive goal.
The difficulty in localizing therapeutics to the core of tumors may largely be due
to a consumption-based barrier to diffusion15 , in which antigen turnover reaches an
equilibrium with diffusion and binding of the therapeutic at a given distance from the
capillary-preventing penetration past that boundary. In the case of A33, perhaps this
barrier is avoided as the antigen is not internalized and degraded on the time scale of
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The simple asset of persistent surface localization, which we have described here,
may account for both of A33's distinctive RIT properties. It may allow the clinical
antibodies to gain tumor specificity as normal epithelium is shed, and to penetrate the
core of a solid tumor as diffusion outpaces turnover. We likewise speculate that this
surface persistence may allow antibodies to A33 to have high availability to a
radionuclide construct in PRIT. Taken together, these results point to A33 as an excellent
candidate for two-step therapies.
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Chapter 3: Effect of Antigen Turnover Rate and Expression Level on Antibody
Penetration into Tumor Spheroids
3.1 Abstract
Poor tissue penetration is a significant obstacle to the development of successful
antibody drugs for immunotherapy of solid tumors, and diverse alterations to the
properties of antibody drugs have been made to improve penetration and homogeneity of
exposure. However, in addition to properties of the antibody drug, mathematical models
of antibody transport' 2 predict that the antigen expression level and turnover rate
significantly influence penetration. As intrinsic antigen properties are likely to be
difficult to modify, they may set inherent limits to penetration. Accordingly, in this study
we assess their contribution by evaluating the distance to which antibodies penetrate
spheroids when these antigen properties are systematically varied. Additionally, the
penetration profiles of antibodies against CEA and A33, two targets of clinical interest,
are compared. The results agree well with the quantitative predictions of the model, and
demonstrate that dosing distal regions of tumors is best achieved by selecting slowly
internalized targets that are not expressed above the level necessary for recruiting a toxic
dose of therapeutic. Each antibody-bound antigen molecule that is turned over or present
in excess incurs a real cost in terms of penetration depth-a limiting factor in the
development of effective therapies for treating solid tumors.
Major portions of this chapter were previously published in:
Ackerman ME, Pawlowski D, Wittrup KD, "Effect of antigen turnover rate and expression level on
antibody penetration into tumor spheroids" Mol Cancer Ther. 2008 Jul;7(7):2233-40.
3.2 Background
Antibody therapeutics promise highly specific tumor targeting. However, their
superior molecular recognition characteristics have not proved to be the magic bullet
once hoped. This is partly due to difficulty in obtaining sufficiently uniform exposure,
particularly in solid tumors. For example, radioimmunotherapy (RIT) has achieved
relative success in treating blood cancers such as lymphoma, where it is emerging as a
promising front-line treatment, but more limited success against solid tumors3. These
discrepant results are reflective of the additional obstacles to delivering drugs to solid
tissue, where efficient delivery depends on the interplay of several unfavorable transport
rates4'5. Particularly significant rate processes include the rate of antibody escape from
the vasculature and the ability of the therapeutic to penetrate tissue .
Antibodies have very low rates of extravasation, making transport across the
vasculature a considerable barrier. For directly conjugated antibody therapeutics, the
resulting concentration profile, where the blood often contains a 100 to 1000-fold higher
concentration of therapeutic than surrounding tissue1 2,6, obviously limits efficacy. When
combined with a long circulatory halflife, the elevated blood concentration often results
in bone marrow toxicity before therapeutic toxicity throughout a solid tumor is reached.
Once out of the vasculature, there are further obstructions to tumor permeation by
antibody drugs. The specific architecture of solid tumors, such as limited convective
.5flow, high interstitial pressure, and a dense extracellular matrix, acts to limit penetration .
The well-studied impediment of the "binding site barrier"7'8 results from the intersection
of the slow diffusion and fast association rates of high affinity antibodies. The combined
effect of these rates is that binding sites closest to the vasculature are occupied before
further penetration occurs. This phenomenon results in a highly heterogeneous
distribution of drug-with areas of saturation surrounding the blood supply, and a
complete lack of antibody in more distal regions9 .
In order to evade these barriers to penetration, numerous alterations have been
made to the composition of the protein drug itself3. Decreased size increases both
extravasation and diffusivity10 '"1 , while albumin binding domains9, 12 and interactions with
FcRn 3' 14 have been engineered in order to lengthen plasma residence time and allow
more therapeutic to extravasate before clearance. Low affinity binders have been shown
to circumvent the binding site barrier and allow a more homogeneous distribution of
therapeutic8, at the unacceptable cost however of significantly reducing the amount of
antibody retained in the tumor.
Despite these efforts, solid tumor penetration remains an elusive goal. To account
for the various processes affecting penetration, the simplified scaling model of Thurber,
et all, describes the relevant kinetic rates and processes determining penetration in
spherical micrometastases and vascularized tumors. For the purposes of the present
experiments with spheroids, the relationships for micrometastases will be tested.
Rearrangement of the Thiele modulus, a dimensionless group describing the ratio of
catabolism to transport, yields an expression predicting the distance (R) that a prevascular
spheroidal metastasis will be penetrated by an antibody (Equation 1).
D[ Ab ],uf
R = g ']"" equation 1
ke(FUM0I,
While many of the parameters in this expression relate to the properties of the
antibody, such as the dose ( 15suface), void fraction (s), and diffusivity (D), the remaining
terms describe antigen properties which could set intrinsic limits to penetration. These
terms include the antigen expression level ([Ag]tumor), and turnover rate (ke). Intuitively,
it is clear how each of these parameters could limit the penetration of a high affinity
therapeutic: the distance each antibody can penetrate before binding depends on the
density of binding sites; and as bound antigen is turned over and replaced, new binding
sites are exposed. In fact, if turnover occurs on a timescale comparable to vascular
escape and diffusion, the result is a bottomless sink for therapeutic and a limit to further
tissue penetration.
Accordingly, we experimentally varied antigen concentration and turnover rate in
order to probe their importance in tissue penetration. Quantitative determinations of the
radius of penetration were achieved by incubating tumor spheroids in fluorescent
antibodies against carcinoembryonic antigen (CEA) and A33. These antigen-specific
properties have been less well investigated than those of the therapeutic protein itself,
despite the fact that under some conditions they may pose an intrinsic limit to tumor
penetration. Identification of the antigen properties that significantly impact tumor
penetration will aid in the selection of targets with favorable profiles and in optimizing
this promising mode of cancer therapy.
3.3 Materials and Methods
Cell and Spheroid Culture
16LS174T and SW1222 cells were cultured as described previously'. Antigen
expression levels were quantified using Quantum Simply Cellular Beads (Bangs
Laboratories, Inc). Spheroids were grown by the hanging drop method 17. Briefly,
approximately 500 cells were suspended in 20 ul of media in each well of a 72 microwell
plate (Nunc 448698) and incubated upside-down at 37*C and 5% CO 2 for 2-3 days.
Spheroids were then transferred to glass coverslip-bottomed dishes (Lab-Tek 155411)
and allowed to adhere for 2 days before imaging. Except where noted, antibodies were
added to culture media after this transfer, and the spheroids at each condition were then
imaged repeatedly over time. Care was taken to ensure that antibody binding did not
result in depletion from the bulk.
Fluorescent Antibodies
The mouse anti-A33 antibody m100.310 was conjugated with Alexa*488
according to the manufacturer's instructions (Molecular Probes A-20181) with an
average of 2.76 fluorophores per antibody. Anti-CEA IgGs M85151a and M111147 were
purchased from Fitzgerald and likewise conjugated with Alexa*488 with resulting
conjugation levels of 1.5 and 1.4 fluorophores per antibody, respectively for experiments
comparing penetration distance with respect to internalization rate, and 2.1 fluorophores
per molecule of antibody M85151 a for all other CEA experiments presented.
Image Collection and Analysis
A Zeiss LSM 510 confocal microscope with a 1.4 NA air lens at 1Ox
magnification on a heated stage was used to collect spheroid images. Image collection
conditions were optimized for each antibody used, and then maintained for all timepoints
in each experiment. Care was taken to analyze images at an appropriate depth from the
coverslip in order to avoid both artifacts based on incomplete adhesion to the coverslip
and attenuation of signal due to the thickness of the sample. Images were transferred to
ImageJ, in which they were despeckled and gated to eliminate background signal,
yielding a binary image. A circular selection area was then drawn around each spheroid
and the macro "spheroidspin" was run (see appendix for macro code). This protocol
draws a line across the selection and gives a pixel by pixel readout of signal intensity on
that line as the image is rotated in 18 projections, each varying by 20 degrees, and
generates a results table listing the readout for each line, the sum of pixels with signal for
each projection, and the average number of pixels with signal across projections. This
average gives the diameter of the spheroid that has been penetrated by fluorescent
antibody in pixels, which are then converted into microns. The penetration distances
reported here are the averages of 3-10 spheroids under each condition, and therefore
represent a total of 90-360 individual measurements of penetration radius. Error bars
represent the standard deviation of the penetration distance between spheroids. However,
at later time points and higher concentrations of antibody, the spheroids become
completely saturated, and the standard deviation reflects variability in spheroid size.
Macro for spheroid analysis
Spheroid Spin Macro Code
var count;
var THRESHOLD;
var DEGPERROTATION;
var TOTALROTATION;
showMessage("Spheroid Spin Macro", "Macro is installed.");
macro "Spheroid Spin"
{
THRESHOLD = 25; / threshold of what is considered an "on" pixel
/ if this value changes, update this line: run("Arbitrarily...", "angle=20 fill");
DEG PER ROTATION =20;
TOTALROTATION = 360;
run("Colors...", "foreground=black background=black selection=yellow");
run("Copy to System");
run("System Clipboard");
// make a line through the middle of image
makeLine(0, getHeight, getWidth, 0);
// make and array
arr = newArray(TOTALROTATION/DEGPERROTATION);
// loop through about the entire rotation, increasing by DEGPERROTATION
for(angle = 0; angle < TOTALROTATION; angle += DEGPERROTATION)
{ // sets an array of intensity values for the line
profile = getProfileo;
count = 0;
/ loop through the array and update our output as well as tally up
// all the "on" pixels
for (j = 0; j < profile.length; j++)
{
setResult("p"+angle, j, profile[j]);
if(profilej] > THRESHOLD)
{
count++;
}}
// add the number of "on" pixels to our output and add that number to
// our array
setResult("p"+angle, 0, count);
arr[angle/DEGPERROTATION] = count;
updateResultso;
// rotate by 20 degrees
run("Arbitrarily...", "angle=20 fill");
}
// now calculate the average number of "on" pixels over all rotations
count = 0;
for(i = 0; i < arr.length; i++)
{
count += arr[i];
}
count = count / arr.length;
// and then add to our results
setResult("avg", 0, count);
updateResultso;
}
3.4 Results
3.4.1 Processing of spheroid images
Spheroids - spherical clusters of growing, self-adhered tumor cells - were used
extensively in this study as a model system intermediate between monolayer tissue
culture and xenografts, to capture the effects of simultaneous diffusion, binding, and
endocytic uptake. Spheroids present a 3-dimensional environment in which cells grow
without any solid or artificial support. At large sizes, spheroids also recapitulate
phenomena of tumors such as hypoxic and necrotic cores1 8. Lacking any blood or
lymph-driven convective flow they provide a reasonable model for transport within the
center of a bulk vascularized tumor19 . After an initial period of growth, they may be
analyzed by either 2-photon or confocal microscopy, or fixed and handled as a
histological specimen.
In this study, spheroids were grown in a hanging drop 7 , allowed to adhere to
coverslips, incubated in the presence of various fluorescently labeled antibodies, and
imaged by confocal microscopy. Raw images (Figure 3.4.1 a) were analyzed in order to
determine the average distance that antibody penetrated into the spheroid at a given time.
After acquisition, images were gated to generate a binary version (Figure 3.4.1b), such
that background signal was excluded. A circular region of interest was drawn around
each spheroid, and pixel-by-pixel intensity was taken along a bisecting diagonal line as
the region of interest was rotated in 18 projections around 3600 (Figure 3.4.1c). The
number of pixels above the selected intensity threshold was summed and then averaged
over all projections, giving the diameter of the spheroid that had been penetrated by label.
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Figure 3.4.1: Processing of spheroid images. (a) Original confocal images were
transferred into ImageJ. (b) They were then processed to eliminate background signal
and generate binary data. (c) A circular region of interest was drawn around each
spheroid, and a readout of pixel intensity along a bisecting diagonal line was taken as the
image was rotated in 18 projections around 360 degrees. The number of pixels with
signal from each projection was then averaged, yielding the diameter of the spheroid that
had been penetrated by label.
3.4.2 Antigen density affects spheroid penetration
Equation 1 predicts that penetration distance, R, will increase proportionally to
[Ab].c,,,,and inversely proportional to [Ag],_,.. Accordingly, a ten-fold decrease in
antigen density is expected to yield a Nr1i0 -fold increase in penetration distance.
Similarly, the model also predicts that a tenfold decrease in antigen density will negate
the effect of a tenfold decrease in antibody dose.
In order to experimentally test these predictions, spheroids were incubated in
either a given concentration of fluorescent anti-A33 antibody, or a mixture of fluorescent
antibody and non-fluorescent competitor. The non-fluorescent competitor functions to
occupy a fraction of binding sites as both antibodies diffuse through the spheroid,
blocking the fluorescent antibody from binding and allowing it to diffuse further into the
spheroid before encountering an available binding site. Accordingly, the non-fluorescent
competitor acts as a means to effectively tune the density of available antigen binding
sites.
When spheroids were incubated in either a given concentration of fluorescent
anti-A33 antibody, or a mixture of one-tenth that concentration of fluorescent and nine-
tenths non-fluorescent competitor antibody, penetration was indeed equivalent (Figure
3.4.2a)-as would be expected given that the total antibody dose is equivalent in both
cases. The decrease in fluorescent antibody dose worsens the signal to noise ratio,
however the equivalence of total dose leads to equivalent penetration distance, as can be
seen in representative images at 24 hours (Figure 3.4.2b and c).
For a given dose of fluorescent antibody, penetration distance is predicted to vary
proportionally to [Ag],_,.. Therefore, when available [Ag]tmor is decreased 10-fold due
to the presence of unlabeled competitor, the model predicts that the penetration distance
will increase by a factor of 10-close to the value observed at a concentration of 0.15
nM at 24 hours (Figure 3.4.2d, black bars). At higher concentrations (gray bars) and later
time points, this ratio decreases to 1, as the spheroids become completely saturated to
their centers under both conditions (error bars represent the variation in spheroid size).
As predicted theoretically1 2 and shown experimentally previously20, increasing antibody
dose is one route to overcoming the binding site barrier.
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Figure 3.4.2: Antigen density affects spheroid penetration. (a) LS174T spheroids
were labeled with 1.5 nM fluorescent A33 antibody (black), or 0.15 nM fluorescent and
1.35 nM non-fluorescent competitor (gray). The penetration distance of the fluorescent
antibody into spheroids under each condition was highly correlated over time. (b-c)
Representative image of an LS174T spheroid at 24 hours labeled with 0.15 nM
fluorescent and 1.35 nM non-fluorescent competitor (b), or 1.5 nM fluorescent antibody
(c). (d) Ratio of penetration for spheroids with differing numbers of available binding
sites (1:10) at 0.15, 0.7, and 1.5 nM doses of fluorescent antibody at 24 and 48 hours.
The penetration ratio is a maximum of 3.2 at the lowest concentration, very close to the
predicted value of -0 (horizontal line). Over time and at greater concentrations, this
ratio approaches a value of 1 as the spheroids become saturated, setting an upper limit on
the penetration distance.
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3.4.3 Penetration studies utilizing different cell lines
In order to explore the dependence on antigen density by an independent method,
spheroids were grown from cell lines expressing different levels of antigen. SW1222
cells express one-fifth as much A33 antigen as LS174T cells (data not shown). This five-
fold decrease in antigen density is predicted to lead to a 5 increase in penetration
distance. As can be seen at 12 hours, 1.5 nM antibody almost completely penetrates the
SW1222 spheroid, while advancing only a few cell layers in an LS174T spheroid (Figure
3.4.3a vs. b). The relative distance that the antibody front penetrates in each spheroid cell
type was quantified and is given over a range of concentrations at 12 hours (Figure
3.4.3c). When these penetration distances are taken as a ratio, they agree well with the
model prediction (Figure 3.4.3d).
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Figure 3.4.3: Antigen density affects spheroid penetration. (a-b) Representative
images of an LS174T (a) and SW1222 (b) spheroids labeled with 1 nM A33 antibody at
12 hours. (c) Penetration distance into SW1222 (black) and LS174T (gray) spheroids at
12 hours. (d) Ratio of penetration (SW1222:LS174T) at 12 (black) and 24 (gray) hours,
and the predicted value of 2.45 (horizontal line).
3.4.4 Antigen internalization and turnover affects penetration
In order to study the effect of internalization rate on penetration, we utilized
antibodies against CEA that exhibit differing internalization rates. Despite binding to the
same cellular target, M85151a and MlI11147 display an approximately 3-fold difference
in internalization rate. This difference is likely related to antibody M85151a's
recognition of two epitopes per CEA molecule, allowing crosslinking of the antigen.
When the increased internalization rate of M85151 a and a 2-fold increase in binding sites
are incorporated into the model, MI 11147 is predicted to penetrate into spheroids 2.3-
fold further than M85151 a. Indeed, when LS 174T spheroids were incubated with each of
these antibodies, there were clear differences in penetration. The more quickly
internalizing M85151 a (t12 5 hours) clearly penetrates the spheroid to a lesser extent than
M111147 (t12 13 hours). Figures 3.4.4a and b are representative sections of spheroids
labeled with M85151a and MS111147, respectively. To quantitatively compare the
difference in penetration, the ratio of the penetration distances of slow to fast
internalizing antibodies was taken at various concentrations (Figure 3.4.4c). Here again,
at early times and low concentrations, before spheroids become saturated and the ratio
approaches unity, the data was found to agree well with the model prediction of a 2.3-
fold difference.
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Figure 3.4.4: Antigen internalization and turnover affects penetration. (a-b)
Representative images of LS174T spheroids labeled with 1.5 nM CEA antibody
M85151a (a) or M111147 (b). (c) Ratio of penetration depth (slow-Mi11147: fast-
M85151a) over a range of concentrations at 48 hours, as compared to the predicted value
of 2.3. At greater concentrations this ratio damps out to a value of 1 as the spheroids
become saturated, setting an upper limit on the penetration distance.
3.4.5 Antigen internalization reaches a steady state with diffusion
Thus, both antigen turnover and antigen density have significant effects on tumor
penetration and should be considered in the selection of targets. While a high antigen
density is beneficial for increasing the exposure of each cell to the therapeutic,
excessively high density inhibits penetration and increases heterogeneity. Likewise,
antigen turnover results in continual replenishment of available binding sites, and can
thereby act as a bottomless sink for therapeutic and block further tissue penetration.
Figure 3.4.5 compares two alternative antigens. Both A33 and CEA are present at similar
expression levels in LS 174T cells and each has a long history of study as a target in
radioimmunotherapy of colon cancer 22-26. However, CEA has a metabolic turnover
halflife of 15 hours, while the halflife of A33 stretches out to almost 60 hours16 . Even
the seemingly slow internalization rate of CEA has a significant effect on tumor
penetration. Figures 3.4.5a and b present the distance penetrated by various antibody
doses over time. A 150 nM concentration of anti-CEA antibody has saturated the
spheroid by the first timepoint, at 6 hours. Therefore, at this concentration, the increase
in the penetration distance beyond that at 6 hours is due to growth of the spheroid, and
this line represents the maximum penetration distance achievable. At low concentrations,
penetration arrests when antibody diffusion comes to steady state with antigen turnover
(Figure 3.4.5a). This arrest is evident as a stalled fluorescence front, which can be
observed in 24 and 48 hour images of cells exposed to 1.5 nM anti-CEA antibody (Figure
3.4.5c top panel). As a result, at this concentration of therapeutic, cells at the center of
the spheroid will never be exposed.
In contrast, the slower internalization rate of A33 not only allows 1.5 nM
antibody (Figure 3.4.5c center panel) to continue to progress towards the center, but even
0.07 nM doses (bottom panel) continue to progress and reach the spheroid center
eventually. Significantly, antibodies to A33 have been shown to accomplish penetration
to the core of tumors in vivo in clinical trials 2 2 2 3-an unusual result for an IgG. We
hypothesize that the slow rate of antigen turnover contributes significantly to this highly
desirable attribute.
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Figure 3.4.5: Antigen internalization reaches a steady state with diffusion and can
limit penetration. Penetration of anti-CEA (a) and anti-A33 (b) antibodies into LS174T
spheroids. At low concentrations, anti-CEA antibody penetration plateaus at a given
radius, while antibodies to A33 accomplish penetration at much lower concentrations. (c)
Representative images of spheroids at 24 (left) and 48 (right) hours with 1.5 nM anti-
CEA Ab (top), 1.5 nM anti-A33 Ab (middle), and 0.07 nM anti-A33 Ab. After 24 hours,
antibody to CEA does not penetrate further into the spheroid mass, despite elapsed time.
3.4.6 Differential turnover and accessibility of A33 and CEA
Therapeutic strategies such as pre-targeted radioimmunotherapy (pRIT),
antibody-directed enzyme prodrug therapy (ADEPT), and antibody-dependent cellular
cytotoxicity (ADCC) rely on sustained accessibility of the tumor-bound therapeutic to a
second agent, and are therefore negatively impacted by internalization. As a means to
study the effect of internalization and turnover on the surface accessibility of antibody
over time, spheroids were grown in antibody, washed, incubated in fresh media, and
imaged daily in order to follow the fate of bound antibody. Over the period of
observation, fluorescent signal may decrease due to antibody internalization and
degradation, or unbinding and diffusion out of the spheroid, or, in the case of CEA, when
antigen is shed. As in previous experiments, spheroids continue to grow over the period
of observation. Therefore, fluorescence is also diluted via the division of labeled cells.
Figure 3.4.6a shows the observed patterns of staining over the course of 4 days after
removal of label. A33 and CEA show dramatically different staining patterns: A33
antibody remains relatively evenly distributed throughout the spheroid, while CEA
exhibits a punctuate localization pattern.
In order to visualize the amount of antibody that remained surface localized 4
days after removal of the antibody from culture media, spheroids were incubated with a
secondary antibody (anti-mouse PE conjugate), washed, and imaged (Figure 3.4.6b).
Strikingly, much of the anti-A33 antibody remains surface-localized and accessible to
secondary, while with the exception of a few punctuate regions, accessible anti-CEA
antibody is largely absent. Considering the secondary labeling antibody as a proxy for
the second agent in any multistep targeting strategy such as PRIT or ADEPT, Figure
3.4.6b illustrates a marked preference for A33 as a target.
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Figure 3.4.6: Differential in-spheroid turnover and accessibility of A33 and CEA
antibody over time. (a) Images of LS174T spheroids grown in A33 (left) or CEA (right)
antibody. Antibody was then removed from the bulk, and spheroids were imaged 1-4
days post removal to follow the localization and persistence of fluorescent antibody. (b)
4 days after label was washed out, spheroids were labeled with an anti-mouse antibody
conjugated with PE, allowing identification of the surface accessible primary antibody.
3.5 Discussion
The limited tissue penetration of antibody drugs is an obstacle to successful solid
tumor immunotherapy and has led to diverse efforts to increase tumor exposure3 . A
variety of drug-level optimizations have been pursued, including increasing diffusivity
and extravasation, extending plasma halflife, and lowering affinity-each aimed to
increase penetration and improve the homogeneity of solid tumor exposure. Similarly,
tumor microenvironment has been manipulated in order to favor better penetration.
Various investigators have studied the effect of altering the extracellular matrix, vascular
transport, and interstitial pressure and transport parameters, often via combination
therapy'' . Clearly, there is widespread recognition that a good penetration profile is
critical to therapeutic success and consequently much effort has been put into optimizing
tumor exposure-both by manipulating drug properties and the tumor microenvironment.
However, less attention has been paid to the properties of the target antigen that
might pose intrinsic limits to penetration. Previous theory predicts that both the
expression level and turnover rate of the antigen can affect penetration' 2. This study
provides experimental evidence that under some circumstances antigen properties can be
the determining factor in tumor penetration, and supports the selection of antigens with
slower turnover and lower expression.
As this report demonstrates, antigen density can have a dramatic effect on tumor
penetration. Of course, the greater penetration observed with lower antigen density is in
direct opposition to the practice of selecting highly expressed tumor antigens in order to
increase the amount of drug to which each cell is exposed. And, somewhat ironically, to
the extent that expression level has been manipulated in targeting, it has been to
upregulate expression via interferon gamma treatment28 , which, as shown here, would be
predicted to decrease overall penetration depths.
In practice, once an antigen is expressed at levels sufficient to recruit a lethal dose
of therapeutic, additional antigen counterproductively leads to poorer tumor penetration,
and a more heterogeneous dosing of the tumor. Since the level of expression sufficient to
induce cytotoxicity may vary widely depending on the mode of therapy used, bounds for
optimal antigen expression levels will be case-specific. Highly potent toxic modalities
such as alpha emitters or some protein toxins may be best suited for low antigen
expression, while other less potent therapeutics may require high expression to be
effective. Nonetheless, regardless of the expression level required for cytotoxic effect,
incremental expression above that level incurs a cost in terms of reduced penetration.
We have also demonstrated that turnover can set an inherent limit to penetration:
if the target is replaced at a rate similar to the diffusion of the therapeutic through tissue,
complete penetration may be impossible. Here too, however, the preferred antigen
turnover rate will depend on the mechanism of cell killing, since internalization is critical
to immunotoxin and antibody-drug conjugate therapies, for example. Slow turnover
remains desirable for penetration, but internalization is necessary for efficacy in such
cases-leaving the goals of reaching distal cells and high drug activity in direct
opposition. In contrast, two step therapies, such as ADEPT, pRIT, or effector function
rely on persistent surface localization and antibody/antigen turnover acts to directly
decrease cell killing. Because altering a single parameter can have multiple and even
competing effects, it is instructive to look to quantitative, predictive models to assess
such tradeoffs when designing therapies. The complexity of relationships between
transport, binding, and other kinetic processes can lead to non-intuitive outcomes which
are captured by a properly formulated model.
Differences between A33 and CEA, the two targets used in this study, likewise
highlight the importance of target-tailored therapy design. The more rapid turnover of
CEA has multiple implications. First, a greater dose of therapeutic is required to achieve
equivalent penetration. Secondly, as time passes, progressively less targeting drug
remains surface localized and able to bind a second agent in a two-step therapy.
Conversely, more molecules of immunotoxin are internalized during a given period of
time, likely making CEA the preferred target for immunotoxin therapy, relative to A33.
In contrast, the relative stability of A33 is especially promising for two-step
therapies. Observations made here as to the ability of antibodies to A33 to penetrate
spheroids at even extremely low doses are paralleled by experience in the clinic, where
even the necrotic centers of tumors are labeled 22,23, and where antibody is detectable a
month and a half after administration. This stable profile would allow for both improved
dosing of distal cells, as well as the recruitment of the toxic effector at a level similar to
antigen expression. The fact that clinically observed differences between the penetration
of antibodies against A33 relative to other targets are reproduced here suggests both that
the spheroids used here are a reasonably representative model of in vivo tumors, and that
antigen properties are indeed relevant to clinical biodistribution results.
While antibody therapeutics have well-demonstrated difficulty in penetrating
tissue, this difficulty is generally ascribed to their large size. However, there is a
significant body of literature describing the inability of even small molecule drugs to
penetrate tissue. Clearly, if even orders of magnitude changes in size, extravasation, and
diffusivity cannot lead to thorough tumor penetration, there are other parameters that
must have a considerable impact on distribution and penetration. Minchinton and
Tannock provide an excellent review of the distribution of small molecules in tumors as a
factor in therapeutic outcome4 . Many of the factors cited to influence antibody
penetration also figure prominently for small molecules, and it is likely that the target
properties explored here can play a similar role in determining the distribution and
efficacy of small molecules.
Overall, the data presented here quantitatively validates the model of Thurber et
al. 1 and demonstrates the importance of antigen-specific parameters in tumor penetration.
As tissue penetration is a significant hurdle in the success of therapeutics, care must be
taken not only to optimize the properties of the drug itself in order to maximize
penetration, but also in the selection of target antigen. Dosing of distal regions of tumors
is best achieved by selecting highly stable targets that are not expressed above the level
necessary for recruitment of a toxic dose of therapeutic. While a high antigen density is
beneficial for increasing the exposure of each cell to the therapeutic, excessively high
density inhibits penetration and increases heterogeneity. Likewise, antigen turnover
results in continual replenishment of available binding sites, and can thereby act to block
further tissue penetration. Each molecule of antigen that is either turned over or present
in excess incurs a real cost in terms of penetration-a significant obstacle to the
development of effective therapies for solid tumors.
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Chapter 4: Multi-step tumor targeting with a bispecific A33 antibody
4.1 Abstract
Here we describe the in vitro characteristics and in vivo biodistribution of a multi-
step tumor targeting therapy utilizing a novel bispecific antibody which recognizes both
the A33 antigen and a small molecule radiometal chelate. This bispecific antibody
consists of a typical IgG molecule with an additional scFv domain fused to the C-
terminus of the IgG light chain, generating a tetravalent molecule capable of recognizing
2 copies of the A33 tumor antigen, and 2 small molecule radiometal chelates. Following
in vitro testing, the A33 bispecific was administered to mice bearing SW1222 xenograft
tumors and its biodistribution was determined. Subsequent preliminary experiments have
characterized the effect of a clearing step utilized to block and eliminate the remaining
blood pool fraction of bispecific prior to administration of a radioactive DOTA chelate
and determinations of its biodistribution and tumor uptake. These studies strongly
support further investigation of the A33 antigen as a target in multi-step immunotherapy.
Major portions of this chapter are the result of collaborations with Kelly Davis, MIT and Peter Smith-
Jones, Memorial Sloan Kettering Cancer Center
4.2 Background
The recent success of several radioimmunotherapeutics has demonstrated proof of
principle for this type of targeted cancer therapy'. Unfortunately, in many potential
applications, bone marrow toxicity limits therapy. In order to circumvent this toxicity, a
two-step strategy, known as pretargeted immunotherapy (PRIT) has been proposed, in
which the targeting construct and radionuclide are separated into two. distinct dosing
steps. In this way, one preserves the specificity of antibody binding in tumor targeting,
but eliminates the toxic effects of long-lived directly labeled antibodies. When compared
to single step therapies using directly labeled antibodies, PRIT has generally lead to
lower toxicity and better efficacy . However, the addition of a separate step constrains
the desirable kinetic attributes of the cellular target in comparison with direct RIT,
immunotoxin therapy, or approaches relying on effector functions. In PRIT, the
competing interests of target saturation, clearance of unbound construct from the
circulation, availability of the construct to chelated radionuclide, sufficient proximity to
the nucleus relative to decay pathlength, and the halflife of the radionuclide must all be
taken into consideration. This study seeks to determine if the A33 antigen, a member of
the immunoglobulin superfamily (IGSF) with homology to cell adhesion 5 and tight
junction-associated (TJ) proteins, possesses the properties particularly suited for PRIT.
The A33 antigen has been a target for immunotherapy of colon cancer in
numerous clinical studies6-13. However, the clinical success of the directly radiolabeled
antibodies used has been limited by both the high level of expression in normal colon,
and high blood and bone marrow toxicity caused by the long plasma halflife of the
antibody. In order to circumvent these toxicities, we have aimed to target the A33
antigen in a multi-step therapeutic strategy, in which a bifunctional antibody-based drug
which possesses recognition domains to both the A33 antigen and small molecule
radionuclide chelate is administered, allowed to clear from blood and normal colon, and
then a small molecule radionuclide, with rapid clearance pharmacokinetics is
administered and allowed to bind to the bifunctional antibody localized to the tumor.
This multistep strategy separates targeting from toxic functionalities and thereby allows
the slow blood clearance to work in favor of better tumor uptake and distribution rather
than against therapeutic success as a cause of dose-limiting toxicity. The subsequent
administration of a small molecule radiometal chelate that is cleared rapidly from
circulation unless bound to the bispecific provides highly specific tumor dosing.
We utilize a novel and simple bispecific antibody format in which an scFv is
fused to the C-terminus of the light chain of an IgG to create an IgG-like bifunctional
antibody. This topology, which has been developed and characterized by Kelly Orcutt in
the Wittrup lab, functions as a general platform to combine two binding specificities, and
retains parental affinity of the binding domains, and IgG-like stability and in vivo
pharmacokinetics. Similarly, simple production and purification after mammalian cell
expression is performed by protein A chromatography. This format, schematized in
Figure 4.2, is a simple standardized platform for the construction of functional bispecific
antibodies.
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Figure 4.2: Schematic of bispecific antibody topology. Design of IgG light chain with
C-Terminal scFv Fusion. Pictorial representation of heavy chain, light chain, and fully
assembled bispecific antibody with indicated N- and C- termini. The light chain is
modified with an scFv fusion to the C-terminus, while a completely native heavy chain is
preserved.
While monoclonal antibodies have shown success in the clinic for a variety of
diseases14 , multi-specific antibodies, with an ability to bind to more than one target, may
further improve clinical efficacy via novel mechanisms. Multi-specific antibodies have
been engineered for a variety of applications including enhanced antibody-dependent cell
mediated cytotoxicity (ADCC)1," 6 , surface-receptor blocking and downregulation 7 ,
simultaneous binding to two soluble effector molecules, and pretargeting tumor cells for
the subsequent capture of radionuclides , drugs 8 , and prodrugs 9.
The simple bispecific format utilized here contrasts sharply with alternatives
including chemical conjugation2 0 , co-expression of two antibodies with different
specificities through the hybrid hybridoma technique2 1, complex alterations to heavy
chain domains22 , recombinant methods to produce scFv fusions, diabodies, scFv Fc
fusions, and single variable domain IgGs, among others which frequently require
construct-specific optimization 7.
Two versions of A33 targeting bispecific were constructed, each incorporating a
different A33-binding variable domaini0 ,28, and an scFv domain capable of recognizing
either fluorescein 29 (ALF) or DOTA30 (ALDO), and tested in vitro. Based on improved
in vivo stability after radiolabeling, studies of ALDO in xenografted SW1222 tumors in
nude mice were undertaken at Memorial Sloan Kettering Cancer Center by our
collaborators, Steve Larson and Peter Smith-Jones. While preliminary, these studies
demonstrate the superior tumor targeting profile of a multi-step strategy, and encourage
the development of clinical protocols utilizing this target as well as the multistep and
clearing agents strategies.
4.3 Materials and Methods
Constructs and protein production
The bispecific format was designed as an scFv fusion to the C-terminus of the
light chain of an IgG. The heavy chain is the same as that of an IgGI and was subcloned
into the mammalian expression vector gwiz (Aldevron cat. #5008) as follows: leader-VH-
CH1-CH2-CH3, where VH is the variable heavy domain and CHI, CH2, and CH3 are the
heavy chain constant domains of IgGI.
The light chain is constructed as leader- VL-VK-(G4S)2-scFv-cmyc, where VL is
the variable light domain and VK is the kappa light chain constant domain. The heavy
chain and light chain were cloned into two separate gwiz plasmids between the pstl and
sall restriction sites. The heavy chain and light chain plasmids were transiently co-
expressed in HEK293 cells (Invitrogen cat. #11625-019). HEK293 cells were grown in
flasks on an orbital shaker platform rotating at 140 rpm at 37*C, 5% C02 and were
subcultured following the manufacturer's protocols.
Co-transfection of heavy and light chain plasmids was performed with
polyethyleneimine (PEI) as the transfection reagent. Briefly, HEK293 cells were
subcultured to a cell density of 0.5 - 0.7 x 106 cells/mL 24 h before transfection.
Immediately before transfection, cells were adjusted to a cell density of 1 x 106 cells/mL.
500 pg of each purified plasmid (1 mg/mL) was added to 19 mL Optipro (Invitrogen cat.
#12309-019). 2 mL of 1 mg/mL polyethyleneimine pH 7.0 (PEI, MW 25,000,
Polysciences cat. # 23966) dissolved in water was added to 18 mL Optipro. Both Optipro
solutions were incubated at room temperature for 5 min. The DNA/optipro solution was
added to the PEI/optipro solution and incubated for an additional 10 min at room
temperature and then added drop wise to 1 L HEK293 culture. Supernatant was collected
6-8 days after transfection. Antibodies were purified by protein A chromatography
(Pierce cat. #22811) following the manufacturer's instructions.
ALF (A33 Light chain bispecific to Fluorescein) and ALDO (A33 Light chain
bispecific to DOTA) constructs were made by overlap extension PCR and Quickchange
mutagenesis. The ALF bispecific antibody was cloned and produced as described above
as an A33 IgG with a 4m5.3 scFv3 1 light chain fusion using the VH and VL domains
from the A33 binding scFv generated from a rabbit antibody28 . The ALDO bispecific
antibody was based on the clinical A33 antibody10 with an affinity matured DOTA-
binding scFv designated C825 (Orcutt et al., manuscript submitted) based on the wild
type 2D12.5 antibody32 . Both scFvs were disulfide-stabilized by introducing two
cysteine residues.
A33 IgG plasmid was produced by introducing two stop codons in the light chain
immediately following the CK sequence via Quickchange PCR.
In vitro testing
Simultaneous Binding Assay
105 trypsinized LS174T cells were washed with 500 pL PBS with 0.1% bovine
serum albumin (PBSA) and incubated with 50 nM bsAb or IgG for 1 h at room
temperature. Cells were then washed once with PBSA and incubated with 100 nM
fluorescein (Fl, Invitrogen A-10466), 100 nM DOTA-biotin chelated with yttrium
(DOTA-Y-biotin), 50 nM bsAb, or 100 pL PBSA. Cells were then washed once with
PBSA and incubated with 20 nM DOTAY-647 or FITC-647. Cells were washed once
before analysis by flow cytometry.
Specificity was verified by preincubation of bispecific or IgG with soluble A33
antigen. Antigen extracellular domain was produced in HEK cells as described as a
fusion to a short glycine-based linker, a sortase A reaction site, and a his tag.
Recombinantly produced A33 antigen was also chemically biotinylated (Pierce)
and used to coat streptavidin beads (Invitrogen 11407) as an alternative to the use of live
cells in analysis of the function of bispecific and IgG.
Synthesis of haptens
DOTA-biotin was synthesized by dissolving Amine-PEG3-Biotin (Pierce 21347)
and p-SCN-Bn-DOTA (S-2-(4-Isothiocyanatobenzyl)-1,4,7,10-tetraazacyclododecane-
tetraacetic acid; Macrocyclics B-205) in dimethyl sulfoxide (DMSO) with a 10 fold
molar excess of triethylamine (TEA, VWR #EM-TX1200-5). The reaction mixture was
vortexed at room temperature for 3 h, and then purified by high performance liquid
chromatography (HPLC). Briefly, HPLC purification was performed on a C-18 reverse-
phase column (Agilent Model 1100 HPLC, 1 x 25 cm, buffer A = 0.05% trifluoroacetic
acid (TFA), buffer B = 0.0425% TFA in 80% acetonitrile, 2 - 100% B gradient for 98
min). Flow through was monitored by absorbance detection at 280 nm. Fractions
containing DOTA-biotin were confirmed using matrix assisted laser desorption /
ionization - time of flight (MALDI-TOF) mass spectrometry (Applied Biosystems Model
Voyager DE-STR).
DOTA-647 was synthesized by reacting 1 mM p-SCN-Bn-DOTA with 1 mM
Alexa Fluor 647 cadaverine (Invitrogen A-30679) in DMSO with 40 mM TEA overnight
at room temperature with rotation. DOTA-647 was purified by HPLC as described above.
Yttrium complexes of DOTA conjugates were prepared by incubating a molar
excess of yttrium nitrate hexahydrate (Sigma 237957) with the DOTA conjugates in 0.4
M sodium acetate pH 5.2 buffer overnight at room temperature. The pH was adjusted to
7.0 with 10 M sodium hydroxide and the solution was diluted with PBSA.
Fluorescein-647 (F1-647) was synthesized by reacting 1 mM (Invitrogen F6130)
with 1 mM Alexa Fluor 647 cadaverine in DMSO with 40 mM TEA and rotating
overnight at room temperature and used without further purification
Affinity Measurements
A33 binding affinities for ALF, ALDO, and A33 IgG were measured using
trypsinized LS174T cells that were washed with PBSA and then labeled with varying
concentrations of bispecific or IgG for a minimum of 3 hours at 37'C. Cells were then
washed once with PBSA and incubated with a 1:200 dilution of protein A Alexa Fluor
647 (Invitrogen P21462) before being washed once again and analyzed by flow
cytometry.
Clearing Agent
Clearing agent consisted of fluorescein or DOTA-dextran conjugates, and was
synthesized by Kelly Orcutt, and its ability to block binding to block the binding of either
fluorescein or DOTA was assessed by incubating bispecific-labeled cells with the
dextran-based clearing agent prior to labeling with hapten using flow cytometry.
In vivo testing
In vivo testing was carried out by Peter Smith-Jones at Memorial Sloan Kettering
Cancer Center according to standard protocols. Briefly, nude mice were inoculated with
human colonic SW1222 cells which were then allowed to grow until tumors reached an
appropriate size34. Bispecific was labeled using the iodogen method3 5 , and the quality
and purity of radiolabeled material was assessed by lindmo assay 36,37 and thin layer
chromatography. Mice were then injected with " 11-labeled bispecific, and at varying
timepoints, biodistribution was determined. In pre-targeting experiments, 24 hours after
0.2 mg 13 II-nALDO bispecific was administered, 31 pmoles[Y-DOTA]-dextran clearing
agent was injected, followed by "'In-containing DOTA was 4 hours later, and animals
were sacrificed one hour later.
4.4 Results
4.4.1 Bifunctionality tests
In order to test the function of the ALF and ALDO bispecifics, both magnetic
beads coated with recombinantly-produced A33 antigen extracellular domain (Figure
4.4.1 a), and a suspension of LS 1 74T human colonic cells (Figure 4.4.1 b) were incubated
with a 50 nM concentration of either ALF or ALDO, and then incubated with either
Flourescein-647 (FL-647), or DOTA-647 hapten, as appropriate. Positive 647 signal in
both cases indicates concurrent binding of both arms of the bispecific-both the A33
variable domain to A33 antigen, as well as the scFv to hapten.
Figure 4.4.1c demonstrates the specificity of these interactions on LS174T cells
using a series of negative controls, in which preincubation with soluble IgG blocks
subsequent labeling with bispecific (wide dash), and preincubation with fluorescein
blocks subsequent labeling with FL-647 (thin line), while IgG, which possesses no anti-
fluorescein scFv domain, is likewise unlabeled by FL-647 (narrow dash). Similarly,
Figure 4.4.ld demonstrates that preincubation with soluble A33 antigen blocks the
binding of the bispecific.
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Figure 4.4.1 Bifunctionality tests: (a) Histogram of ALF bispecific binding to A33
antigen coated beads and detected by Fl-647. (b) Histogram of ALDO bispecific binding
to LS174T cells and detected by DOTA-647 (c) Specificity tests of ALF bispecific
indicating that both A33 and fluorescein binding capabilities are competed by soluble
ligand and therefore specific. (d) Competition with soluble A33 antigen.
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4.4.2 Kd assessments and FcRn binding
The affinity of A33 binding domains were assessed by performing a series of Kd
measurements in which LS174T cells were incubated with excess bispecific at varying
concentrations for a minimum of 3 hours at 37*C, prior to labeling with a Protein A-647
conjugate. Figure 4.4.2 presents Kd (a) and dissociation (b) curves for both the ALF
bispecific and its corresponding IgG derivative. The midpoints, or Kd values for both
IgG and bispecific show excellent agreement. Similarly, ALF and ALDO were incubated
with human colonic cell lines, and measurements of their Kd values were made. Figure
4.4.2c indicates that both retain the same affinity to antigen as their construct of origin
(~1 nM). Additionally, the ability to bind to Protein A indicates that the Fc portion of the
bispecific and antibody constructs are folded properly, indicating that they will likely
have maintained clearance and pharmacologic properties as derived from interactions
with neonatal and Fcy receptors and complement.
As a means to more directly test binding to FcRn, T84 cells, which express the
FcRn receptor responsible for the extended plasma halflife of antibodies were incubated
with a panel of antibodies and bispecific. Because the interaction with FcRn is pH
dependent, proteins were incubated with cells at both pH 6.0 and 8.0, and detected via
labeling with Protein A-488. A pH-dependent interaction is apparent for both the control
rabbit IgG as well as ALF bispecific (Figure 4.4.2d).
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4.4.2 Kd assessments and binding to FcRn: (a) Kd curves for ALF (red) and IgG
(blue). (b) Dissociation curve of ALF and IgG. (c) Kd curves of ALF and ALDO on
human colonic cells. The use of different variable domains and cell lines results in
differing Kd values. (d) FACS analysis of the interaction and pH dependence of rabbit
IgG and ALF bispecific binding to FcRn expressing T84 cells.
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4.4.3 Clearing agent characterization
While the long plasma halflife of antibodies is an excellent feature for increasing
the tumor penetration of these molecules, it can be undesirable in terms of blood toxicity,
even in with a pre-targeted strategy. Because the tumor localized bispecific will be
internalized and degraded at some rate, there are competing interests in terms of having
the maximum amount of bispecific accessible in the tumor, and the minimum amount of
blood exposure. Even with a stable target antigen such as A33, timepoints prior to
complete blood clearance are likely to lead to optimum tumor uptake. Therefore, it is
desirable to have a means to decrease blood exposure without waiting for natural IgG
clearance mechanisms. We theorized that a blood pool blocking or clearing agent could
reduce blood exposure to the radiometal chelate by either blocking the hapten binding
sites on the bispecific remaining in circulation, or by triggering rapid clearance of the
bispecific. In order to have an effect on only the blood pool of bispecific and not
bispecific localized to the tumor, our blocking agent must have a limited ability to
extravasate from the blood stream. Accordingly, we have synthesized a high molecular
weight dextran conjugated with 10-100s of either DOTA or fluorescein molecules.
Bispecific in the blood stream will bind to the hapten conjugated to the dextran, which
results in a functional clearing of the blood pool even if the dextran does not trigger rapid
clearance of these large complexes. Therefore, we undertook in vitro tests to observe
whether the hapten binding sites on the bispecific molecule could be blocked by our
dextran conjugates by preincubating bispecific with the blocking/clearing agent, and then
incubating with antigen coated beads or cells, and detection by Protein A-647, FL-647 or
DOTA-647 (Figure 4.4.3, dextran-DOTA results shown only).
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Figure 4.4.3: Functional tests of blood pool blocking/clearing agent. FACS analysis
of cells incubated with bispecific with and without preincubation with dextran-DOTA
synthesized in either water (aq) or dmso, and negative controls include blocking by
dextran alone.
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4.4.4 In vivo biodistribution of ALDO
Nude mice bearing SW1222 tumors were injected with 3 1i labeled ALDO
bispecific at 20 g per mouse, and biodistribution of bispecific was determined at 4 and
24 hours post injection. Despite having a native Fc domain, ALDO shows a more rapid
blood clearance profile than expected. Interestingly, when bispecific is labeled with a
DTPA-based method rather than the iodogen method used here, the blood clearance
kinetics correspond with IgG (Kelly Orcutt, data not shown), indicating that perhaps the
iodogen labeling method used here is damaging. Despite the more rapid clearance
profile, ALDO bispecific is seen to accumulate in the tumor.
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Figure 4.4.4 In vivo biodistribution of ALDO: The biodistribution of 20 sg of 1311.
ALDO bispecific was determined at 4 and 24 hours post-injection. Uptake is reported as
percent injected dose per gram. Clearance from blood is more rapid than expected (8% at
4 hours as opposed to >30%), but tumor uptake is good.
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4.4.5 Impact of clearing step
In order to assess the utility of the clearing step, mice were injected with either
0.02 mg of bispecific and imaged at 24 hours or 0.2 mg, followed by clearing agent at 24
hours and imaging at 28 hours. The results of these tests are depicted in Figure 4.4.5.
Notably, the clearing agent seems to act not only as a blood pool blocking agent, but
actually does trigger rapid clearance of the bispecific from the blood. Consistent with
this interpretation of the decreased blood values, uptake is seen to increase in the
stomach, which is commonly observed when 1311 metabolites are liberated.
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Figure 4.4.5 Impact of clearing step. Biodistribution of ALDO with and without
subsequent injection of dextran-DOTA clearing agent. The concomitant decrease in
blood levels and increase in stomach uptake are consistent with rapid clearance from the
blood, and degradation to yield 1311 metabolites demonstrated by the increase in stomach
uptake.
4.4.6 In vivo biodistribution of DOTA
Finally, in mice treated with 0.2 mg of '31I-ALDO, followed by dextran-DOTA
clearing agent at 24 hours, I1"In-DOTA-Benzene was injected, and its biodistribution was
determined. Figure 4.4.6a presents the uptake of ALDO and DOTA in these mice.
Notably, though there are significant levels of bispecific in the blood, very little DOTA is
located in that compartment. This result indicates that our dextran-DOTA clearing agent
functions by both accelerating clearance of the bispecific from the blood, but also by
simply blocking the DOTA-binding sites and making them unavailable to bind the 1"In-
DOTA-Benzene administered subsequently. Also, in agreement with the release of
metabolites, the high stomach level of 131 does not cause accumulation of DOTA in the
stomach. In contrast, there is a high level of DOTA detected in the kidneys, as DOTA
undergoes almost exclusive renal clearance. Nonetheless, the tissue with the greatest
DOTA uptake is the tumor, resulting in excellent tumor:normal tissue ratios for many
compartments (Figure 4.4.6b).
In fact, for most organs, tumor:normal tissue ratios are 10 or more. Notably, as
blood toxicity was dose limiting with directly radiolabeled antibody, the multi-step
method employed here leads to tumor:blood ratios of >50. In contrast, this ratio was
typically around 2 in single-step therapy protocols. Similarly, the ratios are much
improved for a number of other tissues as well. Therefore, pre-targeting has achieved its
objective of decreasing the dose-limiting blood toxicity. Unfortunately, the tumor:kidney
ratio is only about 2, and this is likely to be the dose limiting organ, as has been true for
numerous other pre-targeting systems.
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Figure 4.4.6 In vivo biodistribution of DOTA: (a) Biodistribution of 'I-ALDO (black)
and 111In-DOTA-Benzene (red). (b) Tumor:organ uptake ratios of 1"In-DOTA-Benzene
presented on a log scale.
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4.5 Discussion
Though the results presented here are preliminary, they are encouraging and
demonstrate promising outcomes utilizing both this novel bispecific antibody format as
well as use of the A33 antigen as a tumor target in multi-step therapy. We have validated
a treatment system consisting of administration of a bispecific antibody, a dextran-based
clearing agent, followed by a small molecule radionuclide chelate. Other pre-targeting
strategies exist, and have shown promise in both animal and clinical studies38 -41.
Compared to multi-step targeting systems utilizing larger haptens, which can lead to
uptake in other organs due to altered clearance pharmacology, or utilize
streptavidin:biotin, which has high kidney uptake and issues involving endogenous biotin
and immunogenicity42-44 , our system uses simple, well-validated components. DOTA has
a long clinical history as an MRI contrast agent, and antibodies and scFvs have been
studied extensively.
The A33 antigen is a particularly appropriate choice for pre-targeted
radioimmunotherapy on several accounts. First, due to its expression in normal colon,
and resulting clinical observations that A33 antibodies only gain tumor specificity after
elapsed time, it is likely that toxicity to normal colon would be a likely result of single
step treatments. Second, in vitro studies have indicated that A33 is a particularly stable
target, and that antibodies to A33 have improved penetration profiles and tumor surface
persistence compared to other common tumor targets such as CEA45-47. By adopting a
multi-step strategy, we have improved the tumor:blood radiation ratio from about 2 in the
case of directly radiolabeled antibodies to >50.
Furthermore, use of the dextran based clearing or blocking agent has the
possibility to improve pre-targeting in numerous systems, and afford particular gains in
cases in which less stable antigens are targeted. For a more rapidly turned over tumor
target, waiting for bispecific to clear from the blood stream leads to significant turnover
of tumor antigen and resulting degradation of tumor-localized bispecific. In these cases,
it is highly desirable to dose radioactive hapten shortly after injecting bispecific, and in
all cases, the use of an effect clearing or blocking agent allows investigators to inject
hapten when tumor uptake is maximal, rather than when tumor:blood ratio is maximal.
Unfortunately, our system currently suffers from a flaw common to other pre-
targeting strategies: because DOTA undergoes renal clearance, kidney uptake will likely
41be dose-limiting . Interestingly, as DOTA has been considered an excellent choice for
pretargeting due to its rapid clearance, it may be that a slower clearance profile would
decrease kidney exposure, as a longer plasma residence time would allow lower doses to
achieve improved tumor uptake-resulting in much improved tumor:kidney ratios.
Overall, we have demonstrated that the bispecific construct used in these studies
is a robust format, able to maintain the properties of the parental variable domains, is
stable in vivo, accumulates specifically in tumors and is furthermore able to localize
hapten to tumor sites. We have accomplished our end of improving the blood toxicity in
A33 immunotherapy. It remains to be seen whether this improvement leads to improved
therapeutic outcomes, or whether we have simply substituted dose limiting kindey
toxicity for dose limiting blood toxicity. To that end, as mentioned, there are numerous
means by which optimization of reagents and protocols might reduce the high kidney
uptake observed in these preliminary studies.
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Chapter 5: Highly avid magnetic bead capture: an efficient selection method for de
novo protein engineering utilizing yeast surface display
5.1 Abstract
Protein engineering relies on the selective capture of members of a protein library
with desired properties. Yeast surface display technology routinely enables as much as
million-fold improvements in binding affinity by alternating rounds of diversification and
flow cytometry-based selection. However, flow cytometry is not well-suited for isolating
de novo binding clones from naive libraries due to limitations in the size of the
population that can be analyzed, the minimum binding affinity of clones that can be
reliably captured, the amount of target antigen required, and the likelihood of capturing
artifactual binders to the reagents. Here we demonstrate a method for capturing rare
clones that maintains the advantages of yeast as the expression host, while avoiding the
disadvantages of FACS in isolating de novo binders from naive libraries. The
multivalency of yeast surface display is intentionally coupled with multivalent target
presentation on magnetic beads-allowing isolation of extremely weak binders from
billions of non-binding clones, and requiring far less target antigen for each selection,
while minimizing the likelihood of isolating undesirable alternative solutions to the
selective pressure. Multivalent surface selection allows 30,000-fold enrichment and
almost quantitative capture of micromolar binders in a single pass using less than one
microgram of target antigen.
Major portions of this chapter were previously published in:
Ackerman ME, Levary D, Tobon G, Hackel B, Orcutt KD, Wittrup KD. "Highly avid magnetic bead
capture; an efficient selection method for de novo protein engineering utilizing yeast surface display.
Biotechnol Prog. 2009 May-Jun;25(3):774-83.
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5.2 Background
The growing applications of yeast surface display (YSD) reflect several
advantages over alternative technologies'. YSD mimics the protein processing machinery
of higher eukaryotes, thereby minimizing expression biases against the complex protein
structures that require foldases and chaperones for efficient assembly, and allowing
presentation of sequence variants and structural architectures less accessible to
procaryotic hosts2 . In a recent study in which the same cDNA library was transformed
into both phage and yeast display systems, YSD identified three times as many binding
clones, and when cloned back into phage, these additional sequence variants could not be
expressed as functional protein3. Additionally, YSD is amenable to engineering
increased expression, stability, pH sensitivity, and enzymatic properties such as
enantioselectivity 4-6. Thus, yeast serve as an excellent host organism for presentation of
proteins for diverse engineering goals.
Flow cytometry (FACS) is the method of choice for quantitative selection.
FACS permits facile comparison between display level and antigen binding, allowing for
selection without expression level bias, and discrimination between clones with very fine
differences in affinity7. FACS also allows the stringency of the selection to be set in live
time based on actual sample data rather than being rigidly pre-defined. Unfortunately,
while well-suited for affinity maturation, FACS is problematic for the isolation of de
novo binding interactions. Flow cytometry simply cannot directly query a library for the
ability to recognize a target antigen, but instead relies on the acquisition of fluorescence
as a proxy for antigen binding. Most commonly this is attempted by tagging the antigen
and using a fluorescent secondary reagent to identify the clones that have bound the
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target antigen. However, the naYve libraries used in de novo selections are not biased
toward any particular epitope or target molecule, and any binding interaction resulting in
acquired fluorescence will be selected. Accordingly, direct interactions between the
yeast-displayed construct and fluorescent reagents satisfy the selection criteria. In fact,
such an interaction regrettably represents the fittest solution to the selective pressure.
Additionally, an interaction with the reagent may also be the most accessible result as the
fluorophore itself may present the most electronically distinct epitope, and may be
present at multiple sites, granting it an avidity advantage relative to the desired
interaction with the target molecule. These factors promote binding to the secondary
reagent above and beyond any target quality issues such as the heterogeneity,
glycosylation, questionable purity, or improper folding that may trouble antigens
produced for the purpose of such selections.
In order to avoid such undesirable outcomes, steps are generally taken to
minimize the chances of isolating secondary binders and to bias the selection to favor an
interaction with the desired target. For instance, incubation with secondaries can be
performed for a minimum amount of time and at a minimum concentration, the target
itself can be directly conjugated with the fluorescent tag using a site-specific
modification8 , and positive selections against target and secondary can be alternated with
negative selections against the secondary alone. However, even these modifications may
not prove sufficient to steer the system toward isolating the desired interaction.
The efficiency of FACS selections compounds these difficulties and poses a
serious impediment to the isolation of de novo interactions. FACS machines analyze and
sort on the order of 108 cells per hour. To ensure that almost all clones are analyzed at
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least once, a ten-fold excess of the library diversity should be analyzed, requiring a day of
sort time for a library of 108 cells, and setting this size as a reasonable upper limit for the
diversity that can be easily analyzed with this degree of diligence.
Unfortunately, by one estimate, a library of 1010 cells may be necessary to obtain
binders with affinities in the nanomolar range9. As a recent example, a library of 2.3x1 07
clones was FACS selected to identify binders to lysozyme, and the initial hit from this
search had micromolar affinity-so low that it could not accurately be measured using
FACS10. The likely absence of nanomolar binders against any given de novo target is a
considerable obstacle for two reasons. First, weaker binding interactions require that
more antigen be present in the incubation steps in order to captured, as by definition only
half of the antigen binding sites will be occupied when a micromolar binder is incubated
in a micromolar concentration of antigen. For a weak interaction, this can translate into a
significant quantity of antigen. For example, FACS selections of naive libraries typical
require on the order of 10 nmole (hundreds of micrograms) of target antigen.
Additionally, weak interactions have very fast dissociation rates. The halflife of a
micromolar interaction is generally on the order of 5 seconds, and nanomolar binders
only a few minutes. Such a rapid dissociation rate is extremely unfavorable for a
detection scheme requiring a separate incubation in fluorescent secondary followed by a
lengthy selection on a flow cytometer. While pre-incubating the secondary with the
antigen before labeling the yeast or using a directly conjugated antigen can help to offset
such a rapid dissociation rate, it increases the probability of isolating binders to either the
secondary or the conjugated fluorophore as described previously.
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A new selection methodology surpassing these barriers to isolating de novo
binders from naYve libraries is needed. Given the confounding factors described here, the
ideal yeast selection platform would first use no tags, secondary reagents, or proxy read-
outs of antigen binding-preventing alternative solutions to the selective pressure.
Secondly, it would allow rapid screening of upwards of 1010 cells, so that the size of the
library that can be thoroughly searched is limited by library construction rather than by
the selection method. Third, it would have the ability to capture even the very weak
binders likely to be present in a naYve library. Finally, it would do so in a rapid,
inexpensive, and straightforward manner without requiring the production of large
quantities of the target antigen.
Accordingly, we have considered alternatives to FACS with the goal of defining a
technique for isolation of even very weak binders from large populations using a
minimum amount of antigen and secondary reagents. In order to capture weak
interactions, we have coupled the multivalency of YSD with antigen multivalency-
allowing avidity effects to drive the selection. Simple mathematic and geometric
treatments of bivalent binding interactions demonstrate the dramatic effects of avidity".
In a simplified system involving 2 binding sites separated by a flexible linker, bivalency
boosted the effective affinity of the interactions by 4 orders of magnitude12 . As yeast
typically display approximately 50,000 copies of the molecule to be engineered, there is
likely the opportunity to reach interactions that are highly multivalent, and thus have
overall dissociation rates of days as opposed to their monovalent dissociation rates of
seconds.
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A concomitant benefit of multivalent antigen display is that it greatly increases
the effective concentration of the antigen. In fact, the high effective concentration drives
the apparent increase in affinity. Once a yeast cell associates with surface bound antigen,
it encounters a very high local concentration of antigen, favoring the formation of
additional interactions. This fortuitously allows a much smaller amount of antigen to be
used in the selection. As long as the multivalent antigen and yeast are well mixed-
affording each yeast cell the opportunity to contact and associate with the antigen during
the selection, high local concentrations can substitute for the high systemic
concentrations used in a FACS selection, dramatically decreasing the amount of antigen
required.
As a means to present multivalent antigen and capture weak interactions we have
investigated the use of solid surfaces. Successful in phage selections for years, e. coli
selections more recently13 , and having precedence in yeast selection in the form of
mammalian cell-based selections employing density gradient centrifugation14'15 or
monolayer panning 16, the use of synthetic multivalent surfaces represents a logical
extension of past methodology. Here we test a variety of surfaces and demonstrate that
extremely low affinity binders can be captured with high efficiency from large
populations using multivalency and we validate multivalent antigen presentation as a
selection method by successfully isolating confirmed de novo binders from naYve
libraries.
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5.3 Materials and Methods
Yeast Strains and Plasmids
All plasmids were transformed into EBYIO yeast using the EZ Yeast
Transformation II kit (Zymo Research D2004) according to the manufacturer's
instructions. Surface displayed constructs were all expressed as aga2p fusions on the
galactose-inducible, tryptophan selectable plasmids pCT-CON or pCTCON2 and grown
and induced as described previously 17. Table 5.3.1 lists the plasmids used in this study.
Table 5.3.1:
clone scaffold target target type citation affinity
LO.7.1 fibronectin lysozyme protein 10 > 1 uM
L1.5.1 fibronectin lysozyme protein 10 -1 uM
L3.3.1 fibronectin lysozyme protein 10 8 nM
L7.5.1 fibronectin lysozyme protein 10 3 pM
2D12.5 scFv DOTA small molecule 18,19 10 nM
4m5.3 scFv fluorescein small molecule 20 48 fM
his6 tag scFv chelated cobalt small molecule 21 -1 uM
anti-his antibody protein n.a. n.a.
Surfaces
Nickel and streptavidin-coated wells (Qiagen), immunotubes (Nunc), tissue
culture plastic (BD Biosciences), glass slides and nitrocellulose membrane (VWR
International), agarose talon resin (Clontech), and magnetic beads (Invitrogen 101-01D,
110-47, and 162-03) were used as multivalent surfaces.
Flow Cytometry
Cells were labeled for FACS analysis as necessary17 . Lysozyme-binding clones
were identified via labeling with biotinylated hen egg lysozyme (Sigma) followed by
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streptavidin-PE (Invitrogen), or via their c-myc tag by means of a chicken anti-c-myc
antibody (Invitrogen) followed by goat anti-chicken 488 secondary (Invitrogen). His
tagged clones were labeled with biotinylated mouse anti-his6 antibody (Qiagen) followed
by streptavidin-PE. Samples were analyzed on a Coulter Epics XL, or sorted on
FACSAria cytometers after labeling.
Pilot Selections
Briefly, populations of binding and non-binding yeast, usually a ratio of 1:100 or
1:1000, were mixed and incubated with the materials, allowed to bind, and then washed.
Growth media was added to the material and bound yeast were allowed to divide off for a
period of time before enrichment and yield were measured by either FACS or plating, as
described previously 2 .
Agarose Talon Resin: Binding and non-binding yeast were mixed and incubated with 2
ml of washed and equilibrated resin in a 15 ml conical for 1 hour. The yeast slurry
mixture was then poured into a column and washed and eluted per the manufacturer's
instructions. Fractions were diluted into growth media, induced, and FACS was
performed in order to determine the prevalence of binders after the selection.
Plastic, glass, nitrocellulose, and immunotubes: These materials were incubated in a
concentrated solution of lysozyme (>2 mg/ml) in PBS for at least 2 hours at room
temperature, or 4'C overnight on a rocker platform, allowing coating to occur by passive
adherence. A western blot was performed on the nitrocellulose sample in to confirm the
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lysozyme coating. The surfaces were washed with PBS-BSA (0.1%) three times for five
minutes to remove unbound lysozyme. Binding and non-binding yeast were incubated
with the materials for at least 1 hour at room temperature on a rocker platform. Washes
were performed to remove unbound yeast, and growth media was added allowing bound
yeast to divide off the surfaces before an aliquot was removed for subsequent analysis by
either FACS or plating.
Nickel and streptavidin coated wells: These functionalized plastics were handled
similarly except nickel wells were left bare, and streptavidin wells were incubated with
biotinylated lysozyme for the selection.
Biotin Binder magnetic beads: Except where otherwise noted, 2.5 x 106 streptavidin
coated beads (Invitrogen 110-47) were washed twice in PBS-BSA (0.1%) and then
incubated in 100 pl of 350 nM biotinylated lysozyme overnight at 4C in a microfuge
tube on a rotator. Beads were washed twice and then mixtures of binding and non-
binding yeast were added to the beads and allowed to bind for 1-3 hours at 4'C on a
rotator. The beads were then washed and diluted and plated to quantitatively determine
enrichment and yield.
M-270 Amine magnetic beads: 6 x 108 amine functionalized beads (Invitrogen 162-03) in
DMSO were incubated with a 100-fold excess of solid, dry fluorescein-PEG-NHS
(Nektar), or p-SCN-Bn-DOTA (Macrocyclics) and a 1000-fold excess of TEA and
incubated at room temperature overnight on a rotator, then washed twice with DMSO.
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Bound DOTA was loaded with either gallium or yttrium by adding a 100-fold excess of
metal and incubating in a 37*C shaker for 5 hours in 0.4 M ammonium acetate.
Conjugated beads were then washed with PBS-BSA (0.1%) and used in selections as
described above.
Talon magnetic beads: 25 gl of talon beads (Invitrogen 101-01D) were washed twice in
PBS-BSA(0.1%) and then mixed with populations of yeast and handled as described
above.
de novo Library Selection
Two fibronectin libraries, with variation in both loop length and sequence were
used to isolate de novo lysozyme binders. 1-2.5 x 109 yeast from each library were first
incubated with 1 x 107 bare biotin binder beads for 1 hour as a negative selection.
Unbound yeast were then removed and incubated with 4 x 107 lysozyme-coated biotin
binder beads for at least 1 hour as a positive selection for lysozyme binders. Unbound
yeast were removed and discarded. Beads and bound yeast were then resuspended in 5-
50 ml of growth media and yeast allowed to grow off the beads overnight. For
successive rounds of selection, the procedure was repeated as described with the
exception of decreasing the number of lysozyme-coated biotin binder beads to 1x10 7. In
addition, the number of cells used in each round was modified to reduce the number of
cells processed yet maintain at least tenfold sampling of library diversity. After two
selections, a flow cytometric sort for c-myc positive cells was performed to prevent the
accumulation of truncation clones. The library was then diversified as described 0 . Two
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further bead selections and a c-myc flow cytometric selection were subsequently
performed. Plasmids were isolated from the yeast cells, transformed into bacteria,
individual clones were sequenced and their binding properties analyzed and confirmed by
FACS.
Similarly, selections against biotin-streptavidin were performed essentially as
described above, except that multiple negative selections against streptavidin were
performed each round.
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5.4 Results
5.4.1 Profile of Multivalent Selection Methods
The multivalency of yeast display was coupled with multivalent target
presentation utilizing a variety of solid surfaces, as diagrammed in Figure 5.4.1 a, in order
to identify a selection method capable of isolating rare, weak interactions among large
non-binding populations. Each surface was coated with a target molecule and then
incubated with a mixture of yeast, a small fraction of which expressed a protein capable
of binding to the target. Unbound yeast were removed by washing the surface and the
captured yeast were analyzed in order to determine the ability of the surface to enrich
binding clones from the initial mixture.
Profile of Materials Tested
Figure 5.4.1b presents the ability of each surface tested to enrich binding yeast.
Non-functionalized surfaces were coated by passive adherence of the target protein,
lysozyme, to the surface, and the lysozyme-binding fibronectin clone L3.3.1 (nanomolar
affinity) was used as the binding population. Cobalt, or Talon@ conjugated surfaces were
simply washed and then used to select yeast with a surface displayed his6 tag.
Streptavidin coated surfaces were incubated with biotinylated lysozyme and used to
enrich L3.3.1-expressing yeast. The surfaces tested included nitrocellulose, several
plastics, glass, agarose, and magnetic beads. Binding yeast were mixed with a 10 to
1000-fold excess of non-binding yeast, such as EBY100 yeast lacking any display
construct plasmid, or yeast expressing a non-binding construct. Surfaces were incubated
with the mixed yeast population, washed to remove unbound yeast, and the selected yeast
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populations were then either plated or analyzed by FACS to determine the final
prevalence of binding clones. The ability of each surface to select binding yeast was
determined by evaluating the enrichment of the binding clone population (final
prevalence/initial prevalence), which could then be compared the theoretical maximum
enrichment to purity. For all materials, a number of wash and incubation conditions were
tested, and several materials, including each of the functionalized surfaces, had some
ability to enrich binding yeast.
Interestingly, none of the passively coated materials were able to enrich the
lysozyme binding clone L3.3. 1. This inability may be due to our use of a relatively small
protein target and a binder with a conformationally sensitive epitope. Passive adherence
may have partially or completely denatured the lysozyme and destroyed the epitope
recognized by L3.3.1. While larger proteins may avoid complete denaturation when
passively attached, partial unfolding is still likely to both abolish native and generate
novel epitopes-a highly undesirable presentation of the target antigen in a de novo
selection method. So, while a tag-free means to perform selections is desirable, the use
of tag is preferable to altering the conformation of the target antigen-especially as a tag
may be necessary for purification of the antigen even if unnecessary for the selection.
Additionally, if the tag is present at only a single site and is used to immobilize the target
on the selection material, much of its surface may be buried or occluded.
The two surfaces with the best selective profiles identified from these initial tests
were agarose and magnetic beads, and these materials were characterized more
extensively. First, a mixture of yeast expressing either a his6 tagged scFv or a c-myc
tagged fibronectin domain at a 1:4 ratio were incubated with Talon agarose in order to
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test enrichment of the his6-expressing population. The yeast:bead slurry was poured into
a column and washed and eluted. Fractions were then labeled for FACS analysis to
determine the relative prevalence of each population in the various fractions. Figure
5.4.1 c presents the percentage of each yeast population present in each column fraction
and clearly shows the ability of agarose beads in a column format to be used in
selections.
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Figure 5.4.1: Profile of Multivalent Selection Methods. (a) Diagram of multivalent
interaction between yeast and surface. (b)Yeast can be selected by multivalent surfaces:
The ability of each multivalent surface to select and capture binding yeast from a larger
population of non-binding yeast was determined. In each case, the enrichment ratio was
determined and is presented as a fraction of the maximum theoretical enrichment
(enrichment from 1 in 100 or I in 1000 to purity). Non-functionalized materials had no
ability to enrich binders, perhaps due to denaturation of the target protein to the surface.
Functionalized surfaces, including agarose and magnetic beads showed a strong ability to
select binders and were characterized further. (c) Selection on agarose resin in column
format: Talon agarose resin was used to select yeast expressing a His6 tag from a larger
population of c-mye positive yeast. The percent of each clonal population recovered
from wash (fractions 1-8) and elution (fractions 9-11) is given and demonstrates the
ability to isolate binders specifically.
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5.4.2 FACS profile of selected populations
As a direct means of comparison, his6-tagged yeast were mixed with non-binding
yeast at a ratio of 1 in 1000 and then applied to both agarose and magnetic Talon-
functionalized beads. Figure 5.4.2 presents the profile of the initial population as well as
that of the yeast eluted from each type of bead. Despite being present below the
threshold of detection in the initial population (red trace), binding yeast have been
enriched to approximately 1 in 4 yeast by agarose beads (blue trace), and to near purity
by magnetic beads (green trace), indicating the excellent ability of these materials to
isolate binders.
However, since one of the criteria for the selection methodology is use of a
minimum amount of antigen, agarose beads, which by design have a high binding
capacity due to extensive porosity, while ideal for protein purification, are non-ideal for
target antigen presentation as many of these binding sites are likely to be inaccessible to
the yeast. A less porous surface with fewer contours, such as magnetic beads is better
suited for efficient presentation of the target antigen in this regard.
Having demonstrated the ability of several multivalent surfaces to isolate binding
yeast, we next determined whether magnetic beads, the most promising of these surfaces,
met the other criteria for naive library selections.
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Figure 5.4.2: FACS profile of selected populations FACS data presenting the
prevalence of His6 yeast before (red) and after selection on Talon agarose resin (blue)
and magnetic beads (green) demonstrating the excellent enrichment profiles of these
multivalent surfaces.
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5.4.3 Efficiency of magnetic bead sorting
First, we desired a method capable of isolating extremely weak binders, so
magnetic beads were coated with lysozyme and used to select a series of lysozyme-
binding fibronectin domains with affinities spanning a million-fold range from uM to
pM. The weakest clone, LO.7.1, was identified by FACS selections of solubly
multivalent lysozyme 0 , and has such a low affinity that it could not accurately be
measured by FACS, while the tightest binder, L7.5.1 interacts with 3 pM affinity. Figure
5.3.3a presents the enrichment of lysozyme binding clones from non-binding clones at a
starting ratio of 1:1000 (gray bars). The million-fold decrease in affinity has no effect on
the ability of the beads to select the binding clone.
In contrast, when yeast are first incubated with soluble lysozyme and then quickly
washed and allowed to bind to beads as was done previously in the protocol of Yeung
and Wittrup22 , enrichment is highly dependent on affinity (black bars). In fact, this
seemingly minor protocol alteration drastically reduces the ability to enrich the clone
with the weakest binding, which is likely most representative of the binders present in
naYve libraries. In each case, selection depends on the ability to generate and maintain an
interaction between yeast and bead, and the ability of each yeast to interact multivalently
with a bead is dependent on the surface density of the interacting molecules. In utilizing
a soluble target incubation, multivalency is limited by affinity as only some subset of
surface displayed molecules will be bound to the target antigen, and capable of
interacting with the beads. Alternatively, the degree of multivalency that can be achieved
between target-coated beads is set by either the display level of the yeast, or the coating
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density of the target, and is therefore an inherent property of system, and these
parameters can be set to maximize possible valency.
As a means to estimate the lower affinity limit for capture with a target-coated
surface, a rough calculation of the effective concentration of the target can be made by
quantifying the amount of antigen on each bead and dividing that value by the bead
volume, giving an approximate local concentration. The magnetic beads used in this
study present the target antigen at an effective local concentration in the millimolar range,
and therefore may be able to isolate extremely weak interactions.
Having established the ability to isolate very weak interactions, we investigated
the effect of rarity on enrichment. Binding and non-binding yeast were mixed at ratios
varying from 1:10 to 1:100,000 and were bead selected, resulting in the enrichment
values presented in Figure 5.3.3b. For both interactions between a his6 tag and chelated
cobalt, and the LO.7.1 fibronectin clone and lysozyme, enrichment scaled well with the
theoretical maximal enrichment for each initial prevalence (lines), with a maximal
increase in prevalence from 1 in 100,000 cells to 1 in 3 (30,000-fold enrichment). Thus,
magnetic bead selection easily captures rare clones.
One of the limits of FACS selections is that it limits the size of a population that
can be sorted; thus, the number of yeast that can be screened effectively by magnetic
beads was investigated. Lysozyme-binding (LO.7.1) and non-binding yeast were mixed
at a ratio of 1:1000 at total population sizes varying from 5x1 07 to 4x109, and enrichment
values after 1 and 3 washes were determined for each population (Figure 5.4.3c).
Consistent enrichment values were found across all population sizes, and demonstrate
that 4 billion yeast can be straightforwardly surveyed in a single microcentrifuge tube in
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1 hour. Whereas scaling up FACS selections requires either multiple sorters or
significantly more time, magnetic bead selections can be scaled up by simply using a
larger vessel or running several microcentrifuge tube-sized selections in parallel-
allowing even the largest yeast libraries to be screened to high coverage multiplicity with
ease.
In order to evaluate the flexibility of magnetic bead selections, the ability to
enrich clones displaying several different scaffolds capable of interacting with various
targets was investigated. Figure 5.4.3d shows the enrichment values of clones expressing
either fibronectin of scFv domains that recognize both small molecule and protein targets.
Proteins were immobilized on streptavidin-coated beads via a biotin tag, while small
molecules were chemically conjugated to amine-functionalized beads. Binding yeast
were efficiently isolated from a larger population of non-binding yeast, independently of
their displayed scaffold, size of the target antigen, and whether the targets were
chemically conjugated or immobilized via a tag.
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Figure 5.4.3: Efficiency of Magnetic Bead Sorting (a) Affinity: Magnetic bead
enrichment is not dependent on affinity. Lysozyme binding clones with affinities
spanning 6 orders of magnitude were mixed with non-binding EBY100 at a ratio of 1 in
1000 and incubated with either soluble lysozyme for 1 hour followed by a wash and 2
minute incubation with streptavidin coated beads (black bars), or were incubated with
lysozyme-coated beads for 1 hour (gray bars). The ability of each clone to be selected
via the soluble incubation method is highly dependent on affinity, while lysozyme-coated
beads enrich all clones at a very high efficiency regardless of affinity. (b) Rarity:
Magnetic bead sorting enriches binding yeast with an efficiency close to the theoretical
maximum. Yeast expressing a low affinity (micromolar) lysozyme-binding fibronectin
domain were mixed with non-binding EBY100 at varying initial prevalences ranging
from 1 in 100 to 1 in 100,000, and bead selected with resulting enrichment ratios that
scaled well with the theoretical maximum (line), yielding up to 30,000-fold enrichment in
a single selection. *Data not available. (c) Population size: Magnetic bead sorting easily
and quickly processes large populations of yeast. Varying numbers of yeast at a ratio of
1 low affinity lysozyme binder per 1000 non-binders were bead selected. Enrichment
ratios at each population size are presented after 1 and 3 washes, demonstrating that
4x1 0 A 9 yeast can be screened with no loss in enrichment. *Data not available. (d)
Target: Yeast expressing scFv or fibronectin recognizing a range of protein and small
molecule targets were mixed with non-binding EBY100 yeast at a ratio of 1:1000 and
bead selected. Magnetic beads were able to enrich for all scaffolds, targets, and binding
interactions tested.
5.4.4 Yield of magnetic bead sorting
Finally, we tested the yield of bead selections in order to determine the probability
that each binding yeast cell would be captured. Yield is a critical selection parameter in
two respects. The chances of capturing each binding yeast will first influence the
coverage multiplicity used, and secondly determine the ability of the method to act as an
effective negative selection, wherein yeast with undesirable binding properties are
removed from the library population. Figure 5.4.4a shows the percent of binders present
that were recovered from selections of binding yeast (LO.7. 1) present at a ratio of 1 in
1000 non-binders. In most cases, more than three-quarters of the binders present were
successfully recovered, and this fraction declined significantly only when the number of
binders present was comparable to the binding capacity of the beads (several million
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binders) decreasing the likelihood that binding yeast would encounter available binding
sites.
Similarly, Figure 5.4.4b shows the number of yeast isolated from repeated rounds
of selection against streptavidin. After each selection, yeast in the supernatant were
reapplied to fresh streptavidin beads. The number of binders isolated from each round is
approximately equal to 80% of the total number present. Thus, after 4 rounds of
selection, approximately 99.8% of streptavidin-binding clones have been captured,
leaving only 0.16% in the population. The ability to thoroughly deplete the population of
streptavidin binders via such negative selection serves as a highly efficient means to
constrain the undesirable selection of reagent binders and steer the selective pressure of
each positive selection toward the intended target. This restraint of alternative solutions
to the selective pressure represents a significant advantage over negative selections by
FACS, particularly as extremely weak interactions can be captured and because the yeast
do not require subsequent regrowth and induction before positive selection. Therefore,
negative selections using magnetic beads coated with reagents would be useful when
paired with any method of positive selection in order to improve the chances of isolating
the desired binding interaction.
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Figure 5.4.4: Yield of Magnetic Bead Sorting (a) Yield: Magnetic bead sorting
retrieves binding yeast in high quantitative yield. Low affinity lysozyme-binding yeast
were mixed with non-binding EBYl00 at a ratio of 1:1000, and the size of the total
population sorted was varied between 1.2x10^7 and 4x10A9. Bead selections were
performed and the total number binding yeast retrieved after each selections was
compared to the number initially present. Under all conditions, bead selection captured
the majority of binding yeast present, and was not highly dependent on the total number
of yeast present in the selection. (b) Yield of negative selections: Magnetic bead sorting
retrieves binding yeast in high quantitative yield. A fibronectin library was repeatedly
incubated with streptavidin-coated beads as a means to deplete clones capable of binding
to the beads independent of the target ligand. Each negative selection captured 75-80%
of the streptavidin-binding population present. After the 4th negative selection, only
about 0.16% of bead binders remain and yeast can be incubated with target-coated beads
with a dramatically reduced chance of isolating reagent-binders.
5.4.5 Dependencies of magnetic bead sorting
Thus far, we have demonstrated that magnetic beads can be used to isolate highly
rare and very weak binders to both protein and small molecule targets with high
quantitative yield from very large populations. In order to further profile the factors
affecting these selective abilities, we carried out a series of experiments in which
parameters such as the time of incubation and surface density of interacting molecules
were varied. Figure 5.4.5a presents the enrichment of lysozyme binding clones (LO.7.1)
from non-binding yeast after 1 wash when incubated at a starting ratio of 1:1000 for
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varying periods of time. The magnetic beads rapidly isolate the binding population,
showing near maximal enrichment after 1 hour.
Additionally, since the binding affinities that can be captured using this method
are so low, and because in most tests the non-binding population consisted of yeast that
did not express a surface-displayed construct, we undertook extensive testing of negative
controls in order to ensure that only specific interactions were selected. Beads coated
with a given target were used in tests against yeast expressing constructs capable of
interactions with other targets. Four such mismatched pairs were tested, and all
prevalences after selection were comparable to the initial prevalence of 1 in 1000 (Figure
5.4.5b), demonstrating that the enrichment of binding yeast represents a specific
interaction and is not an artifact of a biased comparison, nor the effect of a promiscuous
system.
Lastly, as described previously, this method depends on the number of molecular
interactions or degree of multivalency that can be achieved, and is therefore predicted to
be impacted by both the density of the target ligand coating the beads, and the density of
the construct displayed on the surface of the yeast. Accordingly, Figures 5.4.5c and d
show the effect of construct display level and target presentation level on enrichment. As
expected, the higher the surface density of interacting molecules-whether limited by the
bead or the yeast, the more likely a multivalent interaction can be achieved resulting in
higher enrichment values. Because the yeast expression level is a significant factor in
determining enrichment, care should be taken to ensure use of cultures that have been
induced to express as highly as possible.
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Figure 5.4.5: Dependencies of Magenetic Bead Sorting (a) Time: Magnetic bead
sorting selects binding yeast rapidly. A population of 1 A7 yeast at a ratio of 1 low
affinity lysozyme binder in 1000 non-binding EBY100 were bead selected for various
times and washed once, yielding a halflife of association under 30 minutes. (b)
Specificity of interaction: Despite the very low affinity requirements, selection of yeast
is highly specific. Mismatched pairings of yeast expressing scFvs and target-coated
beads were selected in order to determine the specificity of interaction necessary for
enrichment. The line represents the presort prevalence. (c) Yeast valency: Enrichment is
dependent on yeast valency. Low affinity lysozyme binding yeast were induced for
varying periods of time resulting different densitites of surface expression, and the bead
selected. A clear dependence on the yeast expression level can be observed. (d) Bead
Valency: Enrichment is dependent on target valency. Beads were coated with varying
densities of lysozyme and used to select a low affinity lysozyme-binding clone. A clear
dependence on the density of ligand on the beads is observed regardless of yeast
expression level.
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5.4.6 Demonstrations of Method Utility in de novo Isolation
In order to fully test the ability of the method, we also sought to select de novo
binders from two naYve libraries, including the same fibronectin library utilized to
generate the clones presented in Hackel et al, was selected using lysozyme-coated beads
as opposed to the FACS methodology applied previously, allowing direct comparison of
the two methods. In the bead selections carried out here, each library was first depleted
of streptavidin or bead binders by an initial incubation with beads as a means to avoid
enriching reagent-binding clones. Non-binding yeast were removed from the supernatant
and applied to beads coated with lysozyme. These beads and the yeast bound to them
were then directly transferred into growth media and subsequently induced for the next
round of the process. After 2 such selections, a FACS sort to isolate c-myc positive
clones was performed to remove truncated clones from the population. The clones were
diversified as described 0 , and the resulting population was bead selected twice followed
by a c-myc positive FACS sort. Several clones were isolated, sequenced, and
characterized.
Interestingly, LO.7.1, the initial binder isolated by FACS selections was also
identified in these bead sorts. However, this clone was not the dominant member
(present once in eight sequenced clones) of the selected population, and therefore it
appears as though the bead selections were able to identify additional binders that were
not isolated by FACS. As we cannot determine accurate affinity values by FACS for
such weak binders, it is unclear whether these additional clones represent stronger
binders that happened to be missed by FACS, or weaker ones that FACS could not
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isolate. In either case, the inclusion of additional diversity in subsequent rounds of
evolution is likely to be beneficial, especially given the use of a loop shuffling protocol.
A second fibronectin library was bead sorted in parallel, and clones with nM
binding affinities were isolated following the same protocol-allowing isolation of
validated lysozyme-binding clones from two different libraries in 1 week using only
about 100 pmol (10 micrograms) of target antigen.
Additionally, as a means to demonstrate the excellent ability of the method to
function in negative selections, bead selections were used to isolate clones capable of
discriminating between streptavidin and biotin-streptavidin. Multiple negative selections
against streptavidin with its biotin-binding site unoccupied were performed prior to each
positive selection against biotin-streptavidin. After 6 selections and 2 rounds of
mutagenesis, clones with nanomolar binding affinity to biotin-streptavidin, but
undetectable affinity to streptavidin were isolated (data not shown). This result shows the
robust nature of beads in both positive and negative selections, and the ability to isolate
interactions of interest with a high degree of specificity.
The excellent capabilities of this multivalent selection method establish it as the
method of choice for de novo selections. Bead-based selections followed by mutagenesis
can be iterated, and the success of each round can be assessed by comparing binding to
reagent-coated beads to antigen-coated beads. Once a population displays increased
binding to the target antigen, it can be mutagenized and selection stringency can be
increased in the following rounds. Stringency may be tuned by altering the duration and
frequency of wash steps, decreasing expression of the surface-displayed construct or
decreasing antigen density on the beads. Alternatively, as long as thorough negative
128
selections are performed, a soluble antigen incubation as in the method described by
Yeung and Wittrup can be utilized to increase stringency. Once FACS-detectable (nM)
binders have been isolated via rounds of bead selection with increasing stringency,
affinity maturation can proceed via FACS. Figure 5.4.6 presents a schematic diagram of
the process for generating high affinity binders with high efficiency from naYve libraries.
Overall, by allowing multivalent presentation of the target antigen locally on a
particle surface, the bead selection method described here is able to sort large populations
and quantitatively isolate even weak binders in a highly rapid and efficient manner.
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Figure 5.4.6: Selection Profile for Successful Molecular Evolution: A flow diagram
for successful molecular evolution showing the complementary roles of bead-based and
FACS-based selections in the isolation of proteins with desired binding properties.
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5.4.7 Recommended quality control steps for de novo selections
For de novo selections, several quality control steps are recommended for
best results. First, in order to ensure that even low affinity clones can be reliably
selected, care must be taken to ensure that maximum valency between yeast and beads
can be reached. This end is achieved in two ways: first, the yeast must be induced to a
high expression level; and second, the beads must be saturated with the target antigen in
order to ensure the selection pressure is solely against the intended target, and not against
either empty streptavidin, or biotin:streptavidin complexes, and provides the opportunity
to achieve the highest degree of valency. Provided the antigen is multiply biotinylated, a
small dilution (1 gl) of beads may be incubated with varying amounts of the antigen
overnight, and then beads can be labeled with streptavidin-PE to allow the formation of
avidin sandwiches. The labeled beads can then be analyzed on a flow cytometer, and the
PE signal determined. This signal is proportional to the antigen coating density. The
investigator should ensure that the bead coating conditions used fall into the fully
saturated region, as depicted in Figure 5.4.7a. Conversely, if the target antigen is singly
biotinylated, then coated beads can be labeled with biotin:FITC and a lack of signal
indicates bead saturation. Additionally, one must remove any free biotin from the
preparation of biotinylated target protein, as free biotin will both decrease the surface
density of the target protein and increase the likelihood of isolating binders to
biotin:streptavidin.
Second, care should be taken in properly setting the stringency of each round.
Initial rounds of selection can be carried out without washing the beads. If early washes
are performed, the duration of the wash should be extended, as the wash period largely
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functions to allow rebinding after disruption of yeast:bead complexes due to
resuspension. Means to increase stringency include increasing the number of washes or
temperature of incubation, decreasing the yeast display level, decreasing the antigen
coating density, or performing an incubation with soluble antigen followed by a brief
incubation with beads as described in the protocol of Yeung et al 2. However, most of
these strategies greatly increase the likelihood of isolating streptavidin binders, and
should be used only after multiple negative selections. Additionally, with the exception
of Yeung's method, these strategies are still more highly dependent on the valency than
on affinity, but will gradually enrich higher affinity clones.
Lastly, dilutions of both the negatively and positively selected populations should
be plated in order to compare the number of yeast binding to streptavidin beads versus
target-coated beads, as well as to assess the theoretical diversity of the population. A
history of these counts allows the investigator to determine whether progress is being
made toward engineering the desired interaction. After several selections, if the colony
count for target-coated beads is larger than that for streptavidin beads, then it is likely that
progress is being made in isolating a binder to the target of interest, and the population
ought to be diversified. Such a plot is presented for the progress of selections against
biotin:streptavidin in Figure 5.4.7b.
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Figure 5.4.7: Recommended steps for quality control. (a) Ensuring bead saturation:
1 ul of beads was incubated with varying molar quantities of a multiply biotinylated
target antigen overnight, followed by detection via streptavidin-PE. The region of
maximum fluorescence represents incubation conditions which saturate with the target
antigen. (b) Tracking selection progress: Beads used in negative (streptavidin alone)
and positive (biotin:streptavidin) selections were resuspended in 1 ml PBS-BSA and
washed for 15 minutes. The magnet was applied, supernatant removed, and beads were
again resuspended in 1 mlPBS-BSA. Dilutions of the resulting bead:yeast mix were
plated, and colonies counted. A history of these colony counts over the course of the
selections is presented. The population was diversified after 3 selections, and after 5
selections, FACS analysis confirmed that the population contained nM binders to
biotin:streptavidin with undetectable affinity to streptavidin alone.
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5.5 Discussion
Because of their robust protein processing machinery, yeast are an excellent host
organism for protein engineering efforts. FACS, while an optimal tool for making fine
discrimination among variants7, is less well suited for de novo selections. Accordingly,
we sought an alternative method for early selection rounds that would avoid the
limitations posed by FACS. These limitations include the size of the population that can
be analyzed, the affinity of binding clone that can be reliably captured, the amount of
target antigen needed, and the likelihood of capturing alternative solutions to the selective
pressure. Here we have demonstrated a method for capturing rare clones that maintains
the advantages of YSD, while avoiding the disadvantages of FACS in isolating de novo
binders from naYve libraries. Coupling the multivalency of YSD with multivalent target
presentation allows screening of billions of yeast in a microcentrifuge tube in an hour and
is able to capture even interactions of micromolar affinity.
While previous studies have utilized magnetic beads (MACS) rather than FACS
for the first round of library selection, they have done so in order to select from larger
sized populations, and not to capture weak interactions, and have thus incubated yeast
with soluble antigen rather than pre-coating the magnetic beads. While such a method
still possesses some advantages over FACS, such as less time for target dissociation
during the selection and the ability to screen a larger population, it remains less suitable
for naYve selections than utilizing antigen-coated beads because it requires considerably
more antigen, only captures clones of affinities similar to the concentration of antigen
achieved in the soluble incubation, and has a high risk of selecting reagent binders.
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While the ability to capture weak binders is generally only necessary when no
suitably strong binders are present in a population, the additional inclusion of weak
clones is likely to provide benefits due to the uneven topology of the sequence-fitness
landscape, in which the fittest final solution does not necessarily arise from the fittest
initial solution as some sequence variants have a higher inherent capacity for
improvement.
Moreover, there are some circumstances in which it may be necessary or
beneficial to work with low affinity interactions. For example, when T cell receptors are
engineered to interact with specific peptide-MHC complexes, variants with high affinity
to the complex often interact with moderate affinity to MHC independent of the presence
of the cognate peptide leading to non-specific stimulation, or stimulation when other
peptides are present23. In order to maintain a requirement for peptide, weak interactions
may be necessary. Because such weak interactions are not reliably detectable by FACS,
use of the multivalent bead method described here may be advantageous.
Beyond the ability to isolate weak interactions, the use of multivalent beads
permits a high local concentration of the target antigen to substitute for a high systemic
concentration, decreasing the amount of antigen required for initial selections by almost 2
orders of magnitude. FACS selections often proceed at a 5 p.M systemic concentration,
while beads require far less antigen yet present the target at a mM local concentration-
potentially allowing isolation of binders with extremely weak affinities.
While the method described here does require the use of tags and other reagents,
isolation of reagent-binding clones can be avoided by the use of bead-based negative
selections. This means to scrub populations of reagent binders dramatically increases the
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probability of isolating clones capable of interacting with the desired target. In fact, the
ability to remove some 99.8% of even extremely weak reagent binders in 4 hours makes
the method useful as a negative selection regardless of the method used for positive
selections. Such an effective negative screen is in stark contrast with attempts to use
FACS as a method for negative selections. Negative selections by FACS are generally
ineffective not only because of errors made in droplet sorting, but because the regrowth
and subsequent induction required allows reagent-binding clones with low expression
during the negative selection a second chance during subsequent re-induction to fall into
the sort window. For example, even if negative selections by FACS were able to reliably
decrease the prevalence of reagent binders 100-fold, subsequent regrowth and the
practice of analyzing a 10-fold excess of library diversity would diminish the effect of the
negative selection to a 10-fold reduction in the total number of reagent binders. Given
sort windows typically drawn to capture the top 0.1 to 1% of the population, once
present, reagent-binders are generally impossible to remove from the library by FACS.
Conversely, negative selection by the multivalent bead method described here is able to
reduce reagent binders almost 1000-fold in 4 hours, after which a positive selection can
be carried out without regrowth-greatly diminishing the chances of enriching these
undesirable solutions to the selective pressure.
An improved means to isolate binders from naYve libraries also increases the
utility of both alternative scaffold and human scFv libraries, and decreases reliance on
immunization of mice or other animals followed by subsequent humanization for initial
binding clones. This advance ought to allow isolation of novel binders with greater ease,
speed, and higher probability of success than previous techniques.
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In conclusion, multivalent antigen presentation on magnetic beads allows
microgram quantities of antigen to identify and select even extremely weak binders with
high efficiency from populations of billions of yeast. Magnetic bead selection combines
the advantages of yeast as a protein engineering host and complements the subsequent
use of FACS to isolate variants with improved properties.
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Chapter 6: An in vitro assay to predict clinical B-cell immunogenicity of therapeutic
proteins
6.1 Abstract
Protein therapeutics promise systemic exposure with increased specificity of
action; and as the fastest growing class of approved drugs, they are beginning to deliver
on this promise. However, such biologics pose additional safety concerns due to the their
immunogenicity, or tendency to be recognized as foreign by the immune system. The
resulting adaptive immune response to the therapeutic can lead to both the rapid
clearance of drug prior to any pharmacologic benefit, as well as to severe toxicities.
Unfortunately, particularly with protein drugs which contain non-human components,
there has been no satisfactory pre-clinical means of assessing B-cell, or antibody-
mediated immunogenicity-leading to costly late stage failures, and necessitating time
consuming and complicated animal and safety studies. Here, we describe an in vitro
method of assessing the B-cell immunogenicity of candidate drugs utilizing protein
engineering tools. By combining a human scFv library with a selection technique
capable of isolating extremely weak interactions via avidity, we demonstrate a correlation
between scores using our in vitro assay and the clinical immunogenicity profile of a wide
range of protein drugs.
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6.2 Background
Beginning with the clinical use of human blood products, organ transplants, and
administration of orthologous proteins, it has been recognized that therapeutic proteins
have safety considerations beyond the requirements for small molecules. Namely, such
biologics must be characterized for their immunogenicity, that is, their tendency to be
recognized as foreign and to generate an adaptive immune response. Biologics that
induce such an immune response can cause significant toxicities, including inflammation,
anaphylaxis, complement mediated cell lysis, as well as to have altered clearance leading
to extremely limited efficacy and toxicity. While this is particularly true for proteins
originating from non-human species with no human counterpart, it has been observed
even with completely native human proteins.
In particular, clinical experience with therapeutic antibodies of murine origin has
created an entire industry around the "humanization" of such biologics, in which
numerous methods are available to decrease immunogenicity. For antibodies, initial
strategies included chimeric fusions, in which whole murine domains were simply
replaced by their human counterpart, leaving only the variable domains of murine origin.
Subsequently, complementarity determining region (CDR) and specificity determining
redion (SDR) grafting, in which only a subset of amino acids located in the antigen
recognition domains of the antibodies are of non-human origin'. Sequence comparisons
to germline human antibodies, and computational analysis of residue frequency or rarity
at a given position may also be used to minimize the immunogenicity of a therapeutic
antibody. Collectively, these tools have led to vast improvements in the safety profile of
recombinant antibodies.
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But for other biologics, such as those utilizing plant or bacterial toxins or
enzymes, which have no human ortholog, there are no similar structural, computation, or
comparative tools available to facilitate humanization. Furthermore, there are numerous
cases in which even completely human proteins have led to immune stimulation' 3 . Early
efforts at studying immunogenicity have relied on injecting patients or animals with
therapeutic and then harvesting reactive T-cells and antibodies, mapping the epitopes
they recognize, and then attempting to alter these specific epitopes4-6. The limits of these
studies are fairly obvious in that they are conducted at a very late stage, and are
extremely time-consuming and expensive. Animal studies, including use of mice with
humanized immune systems, have been used frequently 7 with notable success. They
have been most useful when studying variants of a particular protein, and are generally
able to rank the relative immunogenicity between similar proteins 4' . Here also, the limits
of these strategies are clear as immunogenic epitopes are sometimes conserved across
species and sometimes not9' 10. Better tools, particularly those that can be implemented
early in clinical development are clearly needed.
Both arms of the adaptive immune system function in determining the
immunogenicity of a therapeutic protein, and though there is sometimes significant
overlap between the epitopes recognized by both T and B cells, the best means to assess
clinical immunogenicity will involve study of both. Despite having very different
mechanisms of action, both T and B cells have a functional diversity that is generated by
high levels of genetic recombination, and tempered by deletion of variants that are self-
reactive or fail certain checks of quality control".
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In the case of T-cells, as the therapeutic protein is taken up by cells, it is degraded
into peptides and these fragments are presented on MHC class I and II molecules. T-cells
then interact with the peptides bound in the groove of the MHC molecules through their
cognate T-cell receptors (TCRs), and depending on fit and other signals at the
immunological synapse, are stimulated, triggering a cytotoxic response toward cells
displaying this peptide. Several aspects of T-cell biology have made assessments of T-
cell immunogenicity a much more tractable problem for in vitro prediction. First, T-cell
epitopes are linear-allowing simple sequence information to substitute for 3-
dimensional crystal structures. Second, MHC structures are known, and computational
tools exist for evaluating the fit of various peptide fragments in silico 1. Lastly, the pool
of TCRs has a diversity limited enough to be sufficiently covered for testing in vitro.
Together, these factors have allowed the development of in vitro T-cell stimulation
13 1415sassays that are highly predictive of clinical immunogenicity,, i
T-cell stimulation assays can be carried out by culturing either single donor or
pooled T cells with overlapping peptides or whole protein and monitoring stimulation.
These procedures can identify T-cell epitopes with great success, and coupled with
computational modeling tools allowing the fit of various peptides to MHC to be
predicted, have led to excellent ability to remove T-cell stimulatory epitopes from
biologics. Now public and private databases which house this information are available
and published protocols exist for in vitro screens.
However, satisfactory methods for comparable in vitro determination of B-cell
epitopes do not exist. The computational community has worked to develop prediction
tools and databases of mapped linear epitopes, but despite having shown some promise
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with test cases, they are not widely utilized in clinical development, as they tend to suffer
from insufficient predictive quality-" 18 . The prevalence of conformational, or non-linear,
discontinuous epitopes make it a difficult problem to study even by methods which
additionally require crystal structure information. Coupled with this difficulty on the
epitope side, the particulars of B-cell biology, including the vast diversity of antibodies
and their initially low affinity interactions with target antigen, which may be difficult to
detect using standard techniques prior to somatic hypermutation and resulting affinity
maturation make prediction of B-cell epitopes a significant challenge.
The combined effect of these hurdles has been to effectively limit B-cell epitope
determination to being an in vivo problem of study, leaving investigators to inject
biologic, wait for immune response, pull out antibody, map the binding epitopes, then
alter those epitopes somewhat rationally, and repeat-an extremely time consuming,
expensive, and in the case of human clinical studies, far from optimal mode of study.
This strategy has sometimes been performed in animal models, under the supposition that
the same epitopes will be immunogenic in multiple species, but has also been performed
directly and painstakingly in human clinical studies. While animal models have been
useful in ranking the relative immunogenicity of various constructs, as well as in
specifically mapping immunogenic epitopes, the resulting sequence changes have
sometimes been better at reducing immunogenicity in animal models than in humans. An
in vitro means to predict B-cell, or antibody epitopes in humans is clearly needed.
The method described here combines two protein engineering tools: yeast surface
display of a human scFv library constructed for protein engineering efforts 19, and highly
avid magnetic beads, capable of isolating extremely weak specific interactions2 0 , to score
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the B-cell immunogenicity of a given therapeutic candidate. The human scFv library
used was generated by cloning out heavy and light chain variable domains from the
circulating B-cells in 50 adult volunteers resulting in a library of 109 sequences. Because
B-cells in circulation have already undergone negative selection against self proteins, we
theorize that the library will be less reactive toward human proteins than other species. In
fact, there has been some discussion as to this library being non-ideal for engineering
binding interactions against human targets for this reason. Furthermore, we expect that
the diversity of scFv sequences adequately captures the diversity of antibody function in
vivo, and can therefore be used to predict the relative immunogenicity of proteins, as well
as perhaps to identify immunogenic epitopes.
Candidate proteins are biotinylated and immobilized at mM surface densities on
magnetic beads, and then incubated with yeast displaying a library of human scFv
sequences. Yeast capable of binding to the protein-coated beads are selected and
counted. This count provides a means to assess the reactivity of the human antibody
repertoire to a given protein. We demonstrate the ability of this assay to consistently
score human proteins as lower immunogenicity compared to their orthologs from other
species, agreement with clinical immunogenicity for a panel of antibodies used as
therapeutics, and differentiation between protein variants that diverge by as few as 2-8
amino acids, or that have been conjugated with polyethylene glycol (PEG) as a means to
sterically block interaction with the immune system.
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6.2 Materials and Methods
Protein production
9 species of albumin, and 2 IgG's were purchased in high purity from Sigma.
Alginate lyase was produced as described (Griswold, manuscript in preparation), and
pegylated via site specific maleimide-cysteine chemistry. CEA-binding scFv bearing his 6
tags were cloned into pCT-based vectors and produced in YVH10 yeast as described,
and purified using affinity chromatography (Clontech Talon resin). A33 antibodies were
a gift of Gerd Ritter at Memorial Sloan Kettering and the Ludwig Institute. The EGFR
antibody Ab806 was a gift of Jamie Spangler, Massachusetts Institute of Technology.
Immunotoxins were produced as described.
Proteins were biotinylated essentially according to the manufacturer's instructions
(Pierce sulfo-nhs-LC-biotin), except for tuning the relative molar amounts of reagent:
protein, so as to minimize excessive biotinylation. Free biotin was removed by extensive
serial buffer exchange using Amicon spin columns of appropriate molecular weight
cutoffs. Successful biotinylation was confirmed by western blot, and can be quantified
using the Pierce biotin quantification kit. Target biotinylation levels were between 1-3
biotin groups per molecule.
Yeast handling
The scFv library was grown and induced as described19, 23. Briefly, yeast were
thawed and subcultured twice in SD-CAA before induction in SG-CAA at 20'C for 24
hours. Induction quality was assessed by labeling for c-myc expression (Invitrogen
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A21281, A11309) and analysis on a Coulter EPICS flow cytometer for each induced
population prior to use.
Bead coating
Biotin binder magnetic beads (Invitrogen 11047) were coated with protein as
follows. Approximately Ix107 beads (25 pl) were washed twice with phosphate buffered
saline with 0.1% carrier protein (PBS), then incubated with 50 pl of biotinylated target
protein at a concentration of 100 ptg/ml, diluted with 500 ul PBS and rotated overnight at
4*C. Complete coating was confirmed by incubating beads with differing amounts of
target protein, then labeling beads with streptavidin-PE and analyzing on a flow
cytometer, as described20 . A curve of fluorescence versus target protein concentration
was generated, and saturating labeling conditions in which an increase in protein
concentration did not yield an increase in fluorescence were used. Following coating,
beads were washed twice in PBS to remove excess protein.
Assay
For each protein panel, 4x 109 yeast cells were spun down, and in order to deplete
the population of streptavidin binding scFvs, were then incubated with 100 p1l
streptavidin beads at 4'C for 1 hour. The yeast:bead slurry was then placed on a magnet
for 5 minutes, and unbound yeast were removed using a pipet. In some cases, a second
negative selection was also performed against beads coated with a heavily biotinylated
irrelevant protein in order to deplete biotin-binding scFvs from the population. The
negatively selected yeast were then incubated with pooled beads, each coated
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individually with a single protein of interest from the panel being studied for a minimum
of 1 hour at 44C on a rotator. The yeast:bead slurry was again placed on a magnet for 5
minutes, and unbound yeast were removed using a pipet. The remaining beads and yeast
were resuspended in 1 ml of PBS, added to 50 mls of growth media, and subsequently
induced. This process was repeated a second time with pooled beads, and a 10-fold
oversampling of the population bound to beads in the first pass, as determined by optical
density measured immediately following the addition of the selected yeast to growth
media. Following the second bead selection, truncation mutants were removed by
labeling for c-myc expression and collecting all full length (c-myc positive) clones on a
FACSAria sorter. Again, a 10-fold oversampling of the population was sorted.
Following these initial selections, yeast were induced, and for each protein in the
panel tested, 107 yeast, representing at least a 10-fold oversampling, were negatively
selected for bead and/or biotin binding, then incubated with 10-25 pl of beads coated
with each antigen individually for at least 1 hour at 4*C on a rotator. The slurry was
placed on a magnet for 5 min, after which unbound yeast were removed and discarded.
The remaining yeast:bead mixture was resuspended in 1 ml of PBS, and a 50 p1l aliquot
designated wash 1 was removed for serial dilution and plating on SD-CAA to determine
the size of the initially bound population. The resuspended yeast and beads were then
incubated at 4*C for 15 minutes on a rotator, and then placed on the magnet a second
time. Unbound yeast were removed, bound yeast and beads resuspended, and an aliquot
designated wash 2 was removed for plating. This process was then repeated a third time,
and the final bead-bound population was retained for further analysis.
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Plated dilutions were incubated for 2 days at 30'C, and then colonies were
counted. Generally, 2 separate dilutions had countable populations (between 5 and 200
colonies), and these counts were averaged.
Data analysis
All data was collected in triplicate. Because total colony counts are greatly
dependent on the expression level of the yeast2 0 , which can vary significantly from one
induction to another, counts between replicates were not compared directly, but counts
were ratioed to the mean number of yeast bound in each wash population. Analysis
around the mean further allowed the tendency of single high or low counts to greatly
skew the entire data set to be minimized. The average and standard deviation of 3
replicates is presented.
Follow-up experiments
For some data sets, the wash 3 yeast populations isolated against specific proteins
were grown, induced, and subjected to follow-up study. For the albumin and alginate
lyase panel, individually selected populations, as well as clones were subsequently bead-
selected against their specific target as well as other targets and binding counts were
determined. In other cases, the target protein was multiplexed by incubating with
streptavidin-PE, incubated with yeast, and then analyzed by flow cytometry to observe
specific binding.
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Sequencing
Plasmids were collected from selected yeast populations by zymoprep (Zymo
Research D2004), and then transfected into XL-1 blue cells (Stratagene 200130)
according to the manufacturer's protocols. Colonies were picked, grown for 10 hours in
LB Amp with 10% glycerol, and submitted to Agencourt Biosciences for sequencing
using the atermmid primer.
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6.4 Results
6.4.1 Assay process
The B-cell immunogenicity assay is schematized in Figure 6.4.1. Briefly, panels
of similar proteins were assembled and biotinylated. Streptavidin beads were coated with
the proteins of interest, washed twice, combined, and incubated with yeast expressing the
Feldhaus human scFv library. After co-incubation at 4*C on a rotator, tubes were placed
on a magnet, and unbound yeast removed. Bound yeast were regrown, induced, selected
against pooled beads a second time, and then sorted by FACS to remove truncated scFvs.
The resulting population was induced and then selected against each protein in the test
panel individually, and dilutions of the bead-bound yeast were plated to allow the number
of yeast interacting with each protein target to be counted. This basic process was
followed in order to minimize divergence between the populations of selected yeast.
Because the bead-based selections are highly sensitive to the expression level of the
yeast, they were carried out on pooled beads, so that all proteins in the panel were
incubated with a single yeast population. Additionally, negative selections were
performed to remove bead (streptavidin) and biotin binding clones from the population.
These negative selections were performed prior to each positive selection. Only 2 pooled
sorts were performed in order to maintain an appropriate balance of selectivity and
diversity. Because the bound yeast and beads were not washed, but were simply
regrown, a large number of non-binding yeast are carried over each pooled selection.
This is likely due to simply being trapped between the wall of the tube and the beads as
they migrate toward the magnet. Based on the diversity of clones sequenced after
subsequent selection against a single protein target, we concluded that 2 pooled bead
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sorts, followed by one selection against a single protein gave an appropriate balance
between selectivity and diversity. Furthermore, the sizes of all populations analyzed
were maintained such that the number of binding yeast did not exceed the binding
capacity of the beads used, which was experimentally determined.
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Figure 6.4.1: Assay process (a) Initial processing: the scFv library is first depleted of
reagent binders by removing yeast that bind magnetic beads and/or biotin, then enriched
for yeast which bind the proteins of interest by isolating yeast which bind to protein-
coated beads. This process is repeated, and then full length clones are isolated by FACS.
(b) In triplicate, the resulting yeast population is then depleted of reagent binders again,
and then divided into aliquots which are incubated with beads coated with each protein of
interest individually. (c) The bound yeast and bead slurry is washed 3 times, and each
wash population is serially diluted and then plated to determine the number of yeast
expressing scFvs that interact with each protein.
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F
6.4.2 Assay quality control
Because truncated proteins tend to be misfolded and may consequently have
exposed hydrophobic regions, their presence could skew the binding counts via non-
specific interactions. Accordingly, a single FACS sort gated on the c-myc tag located at
the C-terminus of the displayed scFv was conducted to isolate the full-length clones.
Despite the tendency of misfolded truncations to exhibit non-specific sticking, their
prevalence was not increased significantly in 2 rounds of bead sorting, and remained at
roughly the same level as was initially present in the Feldhaus library (Figure 6.4.2a).
In the single protein selections, beads and bound yeast were washed 0 to 2 times
prior to plating. This washing consisted of removal of unbound yeast, resuspension of
beads and remaining yeast, followed by a 15 minute incubation at 4*C on a rotator prior
to placement on the magnet, and yielded 3 separate colony counts. In general the count
before the first wash (wash 1) was very high compared to subsequent counts (Figure
6.4.2b), likely due to the high density of yeast cells present in the incubation mixture
prior to washing (100 million/ml), and resulting passive trapping of non-binding yeast by
migrating beads. Once the beads were resuspended once, the density was significantly
decreased, along with the probability of grossly inflating colony counts via passive
trapping. Accordingly, in the analysis of colony counts, wash 1 was excluded, and the
data presented consists of the wash 2 and 3 counts averaged over triplicate samples.
Because total colony counts are greatly dependent on the expression level of the
yeast , and expression level can vary significantly from one induction to another, counts
between replicates were not compared directly, but counts were ratioed to the mean
number of yeast bound in the panel for each wash population. This prevents any one
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replicate from dominating the analysis due to much higher counts. Similarly, analysis
around the mean further allowed the tendency of single high or low counts within a
replicate to greatly skew the entire data set to be minimized. The average and standard
deviation of 3 replicates is presented.
We determined assay reproducibility by performing 2 separate repeats starting
from the initial library and followed through final plate counts independently. This was
done for both bovine and human albumin (Figure 6.4.2c) and murine and human IgG
(Figure 6.4.2d). Binding counts were centered around the average number of binders for
each wash, and the average number of binders across each triplicate was determined for
each protein. In all analyses, the count for the human protein variant was assigned a
score of one, and the ratio of binding to other targets was calculated. In independent
assays, bovine albumin scored as approximately 3 times more reactive to the scFv library
as human, and murine IgG scored as approximately 6 times more reactive than human.
Across independent tests, there was very good agreement between these values.
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Figure 6.4.2: Assay quality control. (a) Initial library composition: the naive library,
populations singly and doubly selected against pooled beads, and following the FACS
sort were labeled for c-myc expression, demonstrating no strong trend toward selection of
truncation mutants, and their complete removal following FACS. (b) Effect of washes on
binding counts: wash 1, 2, and 3 binding counts against 4 targets of interest,
demonstrating the trends observed for binding count over the course of 3 washes. The
initially high binding counts are likely due to the high density of yeast cells present in the
incubation mixture prior to washing. (c) Assay reproducibility: ratio of yeast binding to
bovine:human albumin in 2 separate replicates starting from the initial library and
followed through final plate counts independently. (d) Assay reproducibility: ratio of
yeast binding to murine:human IgG in 2 separate replicates starting from the initial
library and followed through final plate counts independently.
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6.4.3 Panels of human and orthologous proteins
Next, we tested a panel of albumin from 8 different species, and human albumin
produced from recombinantly in yeast (Figure 6.4.3a). As would be expected given the
de-selection against self-antigens, the scFv library reacts to the lowest extent against
human albumin, yeast-produced recombinant human albumin, and baboon albumin,
which would be predicted to have a high degree of sequence homology. All other species
ranked as more immunogenic. Interestingly, these scores did not directly agree with
phylogenetic similarity to human albumin.
A panel of antibodies were tested, including both a human polyclonal, and 3
antibodies that have been used in the clinic: muA33 and huA33, murine and humanized
antibodies to the A33 antigen, and Ab806, a human antibody which recognizes the
epidermal growth factor receptor24. Murine anti-A33 (muA33) was highly
immunogenic25 , leading to its humanization (huA33). Unfortunately, huA33 retained a
considerable degree of immunogenicity, and 63% of patients treated with huA33
developed an immune response characterized by significant titers of anti-huA33
antibodies 26,27 . Figure 6.4.3b presents the ratio observed of yeast binding to muA33,
huA33, Ab806 and hulgG to hulgG. These ratios agree strongly with clinical experience,
in which murine antibody is highly immunogenic, Ab806 has been safe2 8, and huA33 has
been significantly more immunogenic than many other humanized antibodies.
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Figure 6.4.3: Assay results for albumin and IgG. (a) Ratio observed of yeast binding
to muA33, huA33, Ab806 and huIgG to huIgG. Ratios agree with clinical experience.
(b) Ratio observed of yeast binding to each species of albumin relative to binding to
human albumin. Human albumin, human albumin produced in yeast (y), and baboon
score lowest, as would be predicted based on homology arguments.
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6.4.4 Fine discrimination between protein variants
Because the antibodies and albumin variants tested are rather dissimilar, we next
looked at whether the assay was able to capture differences between proteins with only a
few point mututaions. For this, a panel of carcinoembyronic antigen (CEA) binding
scFvs were produced, include a murine scFv (MFE)29, humanized MFE (hMFE)30 , a
stabilized version of the humanized construct (shMFE) 2, and a high affinity mutant
(sm3e) . These scFvs diverge by 4 to 28 amino acids, and the humanized scFv was
generated using the tools available for antibody humanization described previously. As
would be expected, MFE, the murine scFv scored highest in the immunogenicity assay,
and hMFE, the humanized scFv scored lowest (Figure 6.4.4a). The stability and affinity
engineered clones scored slightly higher than hMFE. It remains to be seen whether these
engineered variants are clinically more immunogenic than hMFE. However, because the
assay is conducted at 4*C in PBS, it is likely that the stabilizing mutations were not
beneficial in our analysis. If the assay were conducted at 37*C in serum, it is possible
that shMFE and sm3e would have scored lower despite having 4 mutations from its
humanized counterpart due better stability and folding at body temperature.
A simple way to reduce immunogenicity is to sterically block interaction of
antibodies with the protein of interest by incorporating a polyethylene glycol (PEG)
moiety3 1 . Therefore, we also tested a highly immunogenic bacterial enzyme, alginate
lyase (AL), with (AL-PEG) and without PEG conjugation at a single, genetically
controlled site (Figure 6.4.4b). It is important to note that the protein content of these 2
constructs is identical except for a single point mutation to allow control of the
PEGylation reaction. Therefore, the difference in binding counts represents the effect
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that PEG has on sterically blocking existing immunogenic epitopes, as none of those
epitopes have been altered. As is observed clinically, PEG conjugation significantly
reduces immunogenicity in our assay.
Lastly, a panel of immunotoxins, consisting of an anti-CD22 scFv fused to
pseudomonas exotoxin A (HA22)32 and a de-immunogenized variant (HA22-8x) 6,33,
which diverges by 8 amino acids were tested. The immunogenic epitopes on the
exotoxin were identified by immunizing mice with immunotoxin, and isolating and
epitope mapping the sites these antibodies recognized. In general, immunogenic epitopes
were altered by the substitution of large hydrophilic residues with glycine or alanine. In
mouse models, HA22-8x had significantly reduced immunogenicity33, and in human
patients, immunogenicity was reduced relative to HA22, but not as significantly
(unpublished data, Pastan and Hansen). In good agreement with the human clinical
results, our assay reported that HA22 was twice as reactive toward human scFvs as
HA22-8x (Figure 6.4.4c).
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Figure 6.4.4: Fine discrimination between protein variants. (a) CEA-scFv panel: 4
anti-CEA scFv's were screened, a murine scFv (MFE, 28 amino acids diverged from
hMFE), humanized scFv (hMFE), stabilized humanized scFv (shMFE, 4 amino acids
diverged from hMFE), high affinity mutant (sm3e, 6 amino acids diverged from hMFE).
(b) Alginate lyase panel: alginate lyase enzyme with (AL-PEG) and without (AL) a
single 20,000 kDa PEG molecule site-specifically attached. (c) Immunotoxin panel:
HA22 anti-CD22 scFv-pseudomonas exotoxin A fusion (HA22) and de-immunogenized
variant HA22-8x (8 amino acids diverged from wild-type immunotoxin).
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6.4.5 Diversity and specificity of selected clones
Results thus far have indicated that our in vitro immunogenicity assay which
counts interactions between clones in a human scFv library and a protein of interest can
capture the difference between human and orthologous proteins (albumin, IgG, and
scFv), recapitulates the clinical immunogenicity profile of a panel of therapeutic IgGs,
captures the steric effects of PEGylation as a means to reduce immunogenicity, and
scores the immunogenicity of an immunotoxin in good agreement with human clinical
data.
As a follow up to the colony count-based scores, clones isolated in wash 3 were
sequenced, and their diversity analyzed. Up to 20 clones isolated against a single target
were sequenced, and no duplicate sequences were found, indicating that the assay
protocol is not so stringent as to eliminate diversity (data not shown). Selectivity was
checked by the induction of single clones isolated from the wash 3 population and then
competition against non-expressing yeast to verify binding to protein-coated beads. All
clones tested demonstrated specific binding to protein-coated beads (Figure 6.4.5) as
determined by their enrichment relative to their prevalence before selection, and some
clones bound with sufficient affinity that they demonstrated FACS-detectable binding to
their target protein (data not shown). Together, these results indicate that we have
achieved selectivity while maintaining diversity.
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Figure 6.4.5 Diversity and specificity of selected clones: 10 clones from the wash 3
population selected against bovine albumin were grown, induced and competed against
non-expressing EBY100 yeast for binding to bovine albumin-coated beads. All clones
were enriched, indicating that all have a specific interaction with bovine albumin.
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6.4.6 Cross-reactivity of selected clones and populations
Lastly, the cross-reactivity of clones was analyzed. Clones isolated to different
species of albumin were tested for their cross-reactivity to albumin from other species.
Bovine, human, and hamster-selected clones, were induced and bead selected against
bovine and human albumin-coated beads, and a number of cross-reactive clones were
identified, as demonstrated by their relative binding counts (Figure 6.4.6a). Interestingly,
the clones isolated against human albumin tended to bind better to albumin from other
species, whereas the clones isolated against albumin from other species tended to bind
best to that species relative to others, particularly human (Figure 6.4.6b). This result,
again, is consistent with the de-selection of scFv sequences that bind human targets in the
initial Feldhaus library.
As a final test, the wash 3 populations that were isolated against alginate lyase
enzyme, with and without PEGylation, were tested for their cross-reactivity. Because all
of the same immunogenic epitopes are present in both constructs, and some are simply
blocked by the PEG moiety, cross-reactivity testing demonstrates the difference in
accessibility of the immunogenic epitopes due to PEGylation. The population isolated
against AL had reduced binding to AL-PEG, indicating that the presence of the PEG
group limited the interaction between some binding clones to their epitopes (Figure
6.4.6c); and similarly, the population isolated against AL-PEG interacted more strongly
with AL (Figure 6.4.6d), indicating that we have not isolated PEG binding scFvs, but
have in fact demonstrated that the incorporation of a PEG group simply diminishes the
likelihood of interaction between existing immunogenic sites, and the scFv displayed on
the surface of yeast. These results agree with animal studies in which subsequent
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injection with AL-PEG following an initial injection of AL, resulted in a 44% decrease in
reactive antibody titers relative to 2 injections of AL (unpublished data, Griswold).
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6.4.6 Cross-reactivity of selected clones and populations: (a) Clones from the wash 3
human selection were tested for their enrichment against human, mouse, and hamster
albumin. For all clones tested, reactivity to at least one of the orthologous albumins was
stronger. (b) Clones from the wash 3 bovine selection were tested for their enrichment
against cow, human, and hamster albumin. For half of the clones tested, reactivity
toward cow albumin was strongest. In only one case was reactivity against human
albumin strongest. Binding of AL (c) and AL-PEG (d) selected clones against AL and
AL-PEG. The presence of PEG decreases binding interactions for AL-binding clones,
and the removal of PEG increases binding interactions for AL-PEG binding clones.
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6.5 Discussion
The B-cell immunogenicity assay described here provides a convenient in vitro
means to assess the clinical safety profile of protein therapeutics using simple colony
counts to measure reactiveness between a yeast-displayed human scFv library and a
protein of interest. We have demonstrated that our assay scores human proteins as less
immunogenic than their orthologs, agreement with clinical immunogenicity for a panel of
antibodies including a humanized antibody with anomalously high clinical
immunogenicity, the passive effects of PEGylation in decreasing immunogenicity, as
well as the ability to make fine discriminations between protein variants that have
relatively few amino acid substitutions. This last result indicates that not only does this
method capture global immunogenicity differences, but could be used to precisely
identify and alter immunogenic epitopes without the need for animal studies.
Furthermore, the use of highly avid magnetic beads eliminates the need for affinity
maturation, and allows rapid screening.
The scFv library used in these studies is a key variable, as it must adequately
capture in vivo antibody diversity. The technique is predicated on the premise the
Feldhaus library is representative of the antibody repertoire in vivo. Because the library
was constructed from circulating adult B-cells, it indeed ought to reflect the result of
negative selection against self-reactive antibody sequences. However, because one of the
mechanisms by which auto-reactive antibodies are resolved is by changing the pairing of
heavy and light chains, and the means of construction for this library shuffled chain
pairings, it is possible that the newly generated pairings restore auto-reactivity. Another
shortcoming of this library is that it does not exhibit the same antibody subtype
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distribution as native diversity. For example, class 6 variable heavy chain domains are
over-represented. Despite these limitations, immunogenicity counts generated using this
library correlate well with expectations based on sequence homology and human clinical
studies. Perhaps this is not surprising as immunogenicity reductions can translate across
species and between individuals. That is, despite the sequence diversity of the antibody
repertoire, the same sites seem to frequently act as immunogenic hotspots. Interestingly,
there are some indications that there is significant overlap between B and T cell epitopes
and that decreasing reactivity toward one arm of the adaptive immune system results in
reduced overall immunogenicity-a result that makes sense given the interconnectedness
of B and T-cell stimulation.
Factors such as formulation, storage, stability at 370C, and interactions with
plasma proteins also have significant effects on immunogenicity 34 , but are not taken into
account by this method. Some alterations to the protocol, such as conducting selections
at higher temperature or in human serum could address these added variables. It is likely
that no single technique for determining immunogenicity will suffice, but that in
combination with T-cell epitope analysis, stability and formulation studies, and
monitoring in animal and early human trials, this in vitro method for assessing B-cell
immunogenicity could help to eliminate the serious side effects and clinical failures
caused by immunogenicity.
Future study, perhaps using an scFv library expressly designed for
immunogenicity prediction, might allow investigation into trends among self-reactive
sequences and immunogenic epitopes, as well as to permit epitope mapping, and allow
the generation of databases of immunogenic epitopes to facilitate development of
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improved in silico methods. Additionally, this study supports the use of antibody
libraries that have not been negatively selected against self antigens in protein
engineering efforts.
As more biologics come to market, there is a need for increased safety
information not required for small molecule therapies. Improved methods for
determination of immunogenicity in preclinical models will facilitate drug development
and improve the safety of biologics. By combining a human scFv library with a selection
technique capable of isolating extremely weak interactions via avidity, we have
demonstrated a correlation between scores using our in vitro assay and the clinical
immunogenicity profile of a wide range of protein drugs, and open the possibility for
identification and removal of immunogenic B-cell epitopes from protein therapeutics
prior to clinical study.
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Chapter 7: In vitro protein-protein fusion catalyzed by sortase A
7.1 Abstract
Chimeric proteins boast widespread use in areas ranging from cell biology to drug
delivery. Post-translational protein fusion using the bacterial transpeptidase sortase A
provides an attractive alternative when traditional genetic level fusion fails. We describe
optimization of conditions for this in vitro protein ligation and report the successful
fusion of 10 pairs of protein domains with preserved functionality - demonstrating the
robust and facile nature of this reaction.
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7.2 Background
The ability to incorporate disparate modular domains within multi-functional
chimeric proteins has revolutionized both the basic and applied biological sciences.
While genetic fusion remains the gold-standard for chimera production, a given pair of
protein domains may fail to express in tandem either in reasonable yield, or with proper
folding and function-thereby limiting the diversity of domains that can be combined.
Fusion protein expression can be particularly difficult when working with recombinant
proteins originating from different hosts.
Post-translational protein fusion would allow native expression of the individual
fusion partners-permitting expression of each domain in the optimum host, as well as
allowing modular pairing and assembly of component domains after expression-
effectively circumventing the diversity-limiting cloning steps of tandem genetic fusion.
A number of systems for protein-protein fusion have been explored, including native
chemical ligation', intein and enzyme based strategies 2,3, and residue specific chemistries
relying on cysteines or unnatural amino acids . Unfortunately, these solutions tend to be
technically challenging, residue rather than site specific, or necessitate the inclusion of
whole additional protein domains to mediate fusion.
Sortase A is a bacterial transpeptidase that covalently attaches proteins to the
bacterial cell wall by cleaving between threonine and glycine at an LPXTG recognition
motif to generate an acyl-enzyme intermediate which then reacts with an N-terminal
glycine, regenerating a native amide bond5 ,6. This chemistry has been increasingly
exploited to site-specifically link proteins displaying the C-terminus LPETG motif to a
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range of substituents 7 possessing a triglycine motif, including fluorophores8 '9,
photoaffinity probes8 , peptide nucleic acids 10, sugars 1 , polymers12 , solid supports 12-14,
and lipid-modified oligoglycine peptides 5 . Conjugation of GFP to cell surfaces9 and to
make GFP multimers has been demonstrated under reducing conditions7, 12. These reports
reveal the broad applicability of sortase A catalyzed addition reactions, and motivated
this study of its use in producing complex fusion proteins.
We describe here tractable in vitro conditions for the site-specific assembly of
diverse, multi-functional fusion proteins. Sortassembly requires only 2 short peptide
tags: a C-terminal LPETGXn tag on one partner, usually incorporated as LPETG-His 6 to
facilitate downstream separation, and a complementary N-terminal triglycine (GGG)
motif on the other domain (Figure 7.2.1). These domains are small and generally
unobtrusive to protein production, yet allow site and stoichiometric control of the fusion
reaction. Furthermore, a suite of proteins may be expressed with these tags allowing for
modular pairing of diverse domains without additional molecular cloning effort.
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7.3 Materials and Methods
Protein Expression and Purification
Sortase-His6 enzyme was expressed essentially as described previously 2 .
Briefly, BL21 e. coli (Invitrogen, Carlsbad, CA) transformed with pHTT27 (a gift of Dr.
Olaf Schneewind, University of Chicago) were induced with 1 mM IPTG for 4 hours
after reaching an OD 60 0 of 0.4. Sortase was extracted with B-per reagent (Pierce,
Rockford, IL) from pelleted cells that had been frozen overnight. The lysate was purified
on Talon resin (Clontech, Mountainview, CA), and buffer exchanged into 50 mM Tris,
150 mM NaCl, pH 8 using a 10,000 MW cutoff spin filter (Pierce, Rockford, IL),
yielding approximately 100 mg of purified enzyme from a 1 L culture.
A33 antigen extracellular domain bearing a His6 tag (A33-LPETG-His6) and all
IgG constructs were produced in HEK293 cells (Invitrogen, Carlsbad, CA) after PEI
transfection with gWIZ plasmids (Genlantis, San Diego, CA) according to the
manufacturer's instructions. Secreted protein was purified by Protein A chromatography
(Pierce, Rockford, IL), or by affinity chromatography using Talon resin (Clontech,
Mountainview, CA).
12GGG-GFP was produced in BL21 e. coli as described
GGG-Gelonin, GGG-Fab, and GGG-albumin were kind gifts from Christopher
Pirie, Mike Schmidt, and Kelly Davis Orcutt.
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Reaction Optimization
The ligation reaction was optimized using A33-LPETG-His6 and GGG-GFP.
Briefly, 20 l test reactions were conducted under a variety of conditions. Each reaction
consisted of LPETGXn and GGG reactants, sortase A, in storage buffer (50 mM Tris,
150 mM NaCl, pH 8) and lOx reaction buffer (60 mM CaCl 2 in lx storage buffer).
Reactant concentrations ranged from 5 to 50 uM, while enzyme concentrations were
varied from 50 nM to 250 uM. The gradient function of a thermocycler was used to vary
reaction temperature, and reaction time was varied by removing aliquots of a large
reaction mix at set intervals, chilling to 4'C, and adding EDTA to a final concentration of
10 mM to stop the reaction. The resulting samples were analyzed by running at 200 V on
12% bis-tris or Tris-acetate gels (Invitrogen, Carlsbad, CA) according the manufacturer's
protocol after the addition of 4x sample dye and 1Ox reducing agent (Invitrogen,
Carlsbad, CA), as appropriate, before being boiled for 10 min. The fusion product,
approximate MW 70 kDa, was visualized after staining with Simply Blue Safestain
(Invitrogen, Carlsbad, CA).
Fusion Pair Tests
A33-LPETG-His6 and IgG-LC-LPETGGS at micromolar concentrations were
reacted with each of the following: GGG-GFP, GGG-Fab, GGG-IgG, GGG-gelonin, and
GGG-albumin (also at micromolar concentrations). Reactions were allowed to proceed
for 2 hours at 37*C after addition of lOx reaction buffer and 100 nM sortase enzyme.
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Western Blotting
For western blots, gels were transferred onto nitrocellulose at 50 V in Invitrogen
transfer buffer and blocked in 5% milk in phosphate buffered saline with 0.1% Tween-
20. An anti-human light chain-HRP conjugate (AbD Serotec, Raleigh, NC) was used to
detect the light chain in the IgG-LC-LPETG fusions, and a murine anti-human A33
antigen (gift of Gerd Ritter, Ludwig Institute, New York) and goat anti-mouse-HRP
(Sigma, St. Louis, MO) were used to detect A33 antigen before and after sortase reaction
in order to quantify the reaction yield. Bands were detected using ECL reagents (Pierce,
Rockford, IL), and where appropriate, quantified using ImageJ (NIH, Bethesda, MD).
Functional Testing
For functional tests of A33-IgG fused to GFP, 1 1A of biotin binder magnetic
beads (Dynal, Invitrogen, Carlsbad, CA) was washed twice in phosphate buffered saline,
0.1% bovine serum albumin (PBSA), and incubated with 250 gl of 850 nM biotinylated
A33 antigen (biotinylation reagent, Pierce, Rockford, IL) in PBSA at 4*C overnight on a
rotator. After beads were washed twice in PBSA to remove free antigen, 10 l of A33-
IgG-GFP sortase reaction mixture was added to the A33-antigen coated beads. The
reaction mix and beads were incubated overnight at 4'C on a rotator, then washed twice
before being analyzed for GFP signal by flow cytometry on a coulter counter epicsXL
(Beckman Coulter, Fullerton, CA). Bare beads and a mock reaction mix excluding
sortase were run as negative controls, and the binding of A33-IgG-GFP was specifically
competed using an excess of soluble A33-IgG. Because both A33-IgG and GFP are
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conformationally sensitive, these tests demonstrate function and proper folding of both
domains.
The functional tests of CEA IgG fused to A33 antigen, a similar protocol was
followed utilizing biotinylated CEA (antibody, Fitzgerald Industries, Concord, MA;
biotinylation, Pierce, Rockford, IL) to coat beads, and an Alexa-488 labeled anti-A33 IgG
(antibody gift of Gerd Ritter, Ludwig Institute, New York; Alexa labeling, Molecular
Probes, Invitrogen, Carlsbad, CA) to detect A33 antigen. Binding of fusion product was
specifically competed using as excess of soluble CEA-IgG.
Example Purification
The A33-GFP fusion was separated from unreacted A33-LPETG-His6 and sortase
enzyme by purification on Talon resin according the manufacturer's protocol, and various
fractions were subjected to SDS-PAGE analysis and western blotting as previously
described.
Sequences of LPETGXn and GGG-containing Proteins
A33-LPETG-His6
ISVETPQDVLRASQGKSVTLPCTYHTSTSSREGLIQWDKLLLTHTERVVIWPFSNKNYIHGELYKNR
VSISNNAEQSDASITIDQLTMADNGTYECSVSLMSDLEGNTKSRVRLLVLVPPSKPECGIEGETIIGN
NIQLTCQSKEGSPTPQYSWKRYNILNQEQPLAQPASGQPVSLKNISTDTSGYYICTSSNEEGTQFCNI
TVAVRSPSMNGGGGSGGGGSLPETGGSGHHHHHH
Anti-A33 IgG LC LPETG
SELQMTQSPSSLSASVGDRVTITCLASEFLFNGVSWYQQKPGKVPKFLIYGASNLESGVPSRFSGSG
SGTDFTLTISSLQPEDVATYYCLGGYSGSSGLTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASV
VCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEV
THQGLSSPVTKSFNRGECGGGGSGGGGSLPETGGSG
Anti-A33 IgG HC
EVQVMESGGGLVKPGGSLRLSCAASGIGFSHYGISWVRQAPGKGLEWVAYIYPNYGSVDYASSV
NGRFTISLDNAQNSLYLQMNSLRAEDTAVYFCARDRGYYSGSRGTRLDLWGQGTLVTVSSASTK
GPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVT
VPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMIS
RTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGK
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EYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWES
NGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK
GGG-GFP
GGGLNDIFEAQKIEWBEMVSKGEELFTGVVPILVELDGDVNGHKFSVSGEGEGDATYGKLTLKFI
CTTGKLPVPWPTLVTTLTYGVQCFSRYPDHMKQHDFFKSANMEGYVQERTIFFKDDGNYKTRAE
VKFEGDTLVNRIELKGIDFKEDGNELGHY.LEYNYNSliNVYIMADKQKNGIKVNFKEUIMEDGSVQ
LADHYQQNT'PIGDGPVLLPDNHYLSTQSALSKDPNEKRDHMVLLEFVTAAGITLGMDELYKLEHH
HUMH
Anti-CEA GGG-IgG LC
GGGGGSENVLTQSPSSMSVSVGDRVTIACSASSSVPYMHWLQQKPGKSPKLLIYLTSNLASGVPS
RFSGSGSGTDYSLTISSVQPEDAATYYCQQRSSYPLTFGCGTKLEIKATVAAPSVFIFPPSDEQLKSG
TASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVY
ACEVTHQGLSSPVTKSFNRGEC
Anti-CEA GGG-IgG HC
GGGGGSQVKLEQSGAEVVKPGASVKLSCKASGFNIKDSYMHWLRQGPGQCLEWIGWIDPENGD
TEYAPKFQGKATFTTDTSANTAYLGLSSLRPEDTAVYYCNEGTPTGPYYFDYWGQGTLVTVSSPS
TKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSV
VTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTL
NHSRTPEVTCVVVDVSBEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWL
NGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVE
WESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVWffiALHNHYTQKSLSLSP
GK
Anti-CEA GGG-Fab LC
GGGGGSEN-VLTQSPSSMSVSVGDRVTIACSASSSVPYM14WLQQKPGKSPKLLIYLTSNLASGVPS
RFSGSGSGTDYSLTISSVQPEDAATYYCQQRSSYPLTFGCGTKLEIKATVAAPSVFIFPPSDEQLKSG
TASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVY
ACEVTHQGLSSPVTKSFNRGEGSHHHHHH
Anti-CEA GGG-Fab HC
GGGGGSQVKLEQSGAEVVKPGASVKLSCKASGFNIKDSYMHWLRQGPGQCLEWIGWIDPENGD
TEYAPKFQRKATFTTDTSANTAYLGLSSLRPEDTAVYYCNEGTPTGPYYFDYWGQGTLVTVSAGT
KGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVV
TVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSNASGWSHPQFEK
GGG-gelonin
GGGISEFGSSRVDLQGLDTVSFSTKGATYITYVNFLNELRVKLKPEGNSHGIPLLRKKCDDPGKCF
VLVALSNDNGQLAEIAIDVTSVYVVGYQVRNRSYFFKDAPDAAYEGLFKNTIKTRLBFGGSYPSLE
GEKAYRETTDLGEEPLRIGIKKLDENAIDNYKPTEIASSLLVVIQMVSEAARFTFIENQHU,4NFQQRIR
PANNTISLENKWGKLSFQIRTSGANGNff SEAVELERANGKKYYVTAVDQVKPKIALLKFVDK
DPKAS
GGG-albumin
GGGGGSDAHKSEVABRFKDLGEENFKALVLIAFAQYLQQCPFEDHVKLVNEVTEFAKTCVADES
AENCDKSLHTLFGDKLCTVATLRETYGEMADCCAKQEPERNECFLQHKDDNPNLPRLVRPEVDV
MCTAFHDNEETFLKKYLYEIARRBPYFYAPELLFFAKRYKAAFT'ECCQAADKAACLLPKLDELRD
EGKASSAKQRLKCASLQKFGERAFKAWAVARLSQRFPKAEFAEVSKLVTDLTKVHTECCHGDLL
ECADDRADLAKYICENQDSISSKLKECCEKPLLEKSHCIAEVENDENVADLPSLAADFVESKDVCK
NYAEAKDVFLGNTLYEYARRBPDYSVVLLLRLAKTYETTLEKCCAAADPBECYAKVFDEFKPLV
EEPQNLIKQNCELFEQLGEYKFQNALLVRYTKKVPQVSTPTLVEVSRNLGKVGSKCCKBPEAKRM
PCAEDYLSVVLNQLCVLBEKTPVSDRVTKCCTESLVNRRPCFSALEVDETYVPKEFNAETFTFHAD
ICTLSEKERQIKKQTALVELVKBKPKATKEQLKAVMDDFAAFVEKCCKADDKETCFAEEGKKLV
AASQAALGL
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7.4 Results
7.4.1 and 7.4.2: Sortassembly reaction and optimization.
The reaction is typically carried out in pH 8.2 buffered Tris containing 6 mM
CaCl 2 and 150 mM NaCl. We systematically varied and optimized reaction conditions
using A33 antigen as a model LPETG-containing substrate and triglycine-GFP as its
fusion partner. This optimization was done in reaction volumes as low as 20 pl before
determination of ideal conditions to be used in large scale reactions. Overall, the reaction
was robust and there was good fusion product yield under a broad range of conditions,
permitting the stability and sensitivities of the proteins being ligated to determine reaction
conditions rather than a narrow catalytic window. Briefly, ligation product was maximal
under slightly alkaline conditions with high substrate concentrations in a reaction at 42'C
for 1-4 hours with dilute sortase A. Perhaps surprisingly, as sortase A natively functions
at 37*C, higher temperatures can produce a greater yield of fusion product (Figure
7.4.la), and are recommended as long as the proteins being fused are not thermolabile.
For proteins with pH sensitive conformations, the pH of the reaction may be varied
between 7.0 and 9.0 while maintaining high yields (Figure 7.4.1b). High concentrations
of reactants ought to be used (Figure 7.4.1c) and the reaction may be pushed toward
completion by adding an excess of either fusion partner (Figure 7.4.2b). At a 1:1 molar
ratio of reactants, typical fusion protein yields range from 40-75% of the maximum
theoretical yield, while with a 20-fold excess of one reactant, the reaction can proceed to
approximately 85% yield (Figure 7.4.2 c,d).
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Figure 7.4.1 Optimization of sortassembly reaction conditions (a) Yield of fusion
product at different reaction temperatures. Optimal temperature is between 37 and 46*C.
34 35 36 38 41 44 48 51 54 56 57
0 20 30 31 32 33 34 36 37 41 43 44 45 46
(b) Yield of fusion product at different reaction pH values.
6.2 6.4 6.6 6.8 7.0 7.2 7.4 7.6 7.8 8.0 8.2 8.4 8.6 8.8 9.0
MA,qm~
(c) Yield of fusion product in reactions with 55 uM total reactants at differing ratios of
A33-LPETGXn and GGG-GFP. High concentrations of each reactant leads to higher
yield of fusion product.
reactants (uM)
GGG-GFP
A33-LPETGX
Fused A33-GFP
55 55 55 55 55 55 55
1 1 1 1 2 5 10
10 5 2 1 1 1 1
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N-terminus
GGGSLPETGXn
C-erminus
GGGSLPETGG
Y
b reactants (uM) 55 30 15 10 15 30 55 C
GGG-GFP 5 5 5 5 10 25 50
A33-LPETGXn 50 25 10 5 5 5 5 d 16
Fused A33-GFP 0 ae 00225 12
0 2 4 8 15 30 ih 2 4 6 8 10 12 24 O 8
4
Figure 7.4.2: Sortassembly reaction and optimization. (a) Schematic illustration of
sortase A mediated reaction fusing two proteins. (b) Gel of fusion product demonstrating
that excess of either reactant pushes reaction toward completion. Western blot (c) and
quantification (d) showing amount of unreacted LPETGXn substrate before (left) and
after (right) reaction. (e) Coomassie gel of fusion product at various reaction times.
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7.4.3 Optimization of sortase concentration
Care must be taken, however, in tailoring the concentration of sortase enzyme, as
adding excess enzyme reduces the amount of fusion product either by inhibiting
formation of the ternary complex, or by increasing the overall rate of an irreversible
hydrolysis reaction of the LPETG motif, which releases LPET as a terminal product. For
equimolar fusion partners, a 0.1 molar equivalent of enzyme gave optimal fusion product
yield (Figure 7.4.3a)-though this fraction changes as the ratio of reactants is varied
(Figure 7.4.3b). Similarly, this hydrolysis reaction impacts the time allowed for the
reaction to proceed. Because the LPETG motif is present in the desired fusion product,
the enzyme will continue to react with fusion product, and over extended periods of time
the irreversible hydrolysis reaction will outweigh any marginal increases in product yield
as all substrate and product becomes hydrolyzed. Experimentally, the optimal reaction
time is between 1 and 4 hours (Figure 7.4.2e), after which EDTA may be added to
quench the reaction.
A Equimolar reactants
Ratio .01 .02 .04 .1 .2 .4 1 2 5
Fusion product *4 4*
Sortase
B 10:1 excess GGG-GFP
Ratio .01 .02 .04 .1 .2 .4 1 2 5
Fusion product
Sortase
Figure 7.4.3 Optimization of enzyme quantities: The ratio of sortase enzyme to total
reactants (25 uM) was varied under conditions with equimolar A33-LPETGXn and
GGG-GFP (a), and with a 10-fold excess of GGG-GFP (b) in order to identify conditions
with maximal fusion product yield.
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7.4.4 Separation of product and reactants
For separation of product from reactants and enzyme, a His6 tag can be
incorporated both after the LPETG motif and on the sortase enzyme, allowing unreacted
substrate and enzyme to be removed simply by passing over an affinity column (Figure
7.4.4). Product may then be separated from the tri-glycine reactant by methods such as
size exclusion or ion exchange chromatography or through the inclusion of a second tag
on the LPETG reagent. In optimized reactions we have been able to achieve 85% yields
of fusion protein, with reagents and enzyme undetectable after downstream separations.
~o
product
unreacted
A33-LPETG-His6
sortase
Figure 7.4.4: Example purification step demonstrating efficient removal of sortase
enzyme and unreacted A33-LPETG-His6 from a reaction mixture following affinity
chromatography.
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7.4.5 and 7.4.6 Structures of sortassembled domains, reactions, and functional
testing
To assess the diversity of pairings that could be produced through sortase-
catalyzed fusion reactions, we generated GGG- and LPETGXn derivatives of a variety of
representative modular domains, including enzymes (gelonin), antibodies (IgG, Fab),
fluorescent protein (GFP), and cell surface and blood proteins (A33 antigen and albumin)
(Figure 7.4.5), produced in a range of hosts, including e.coli, yeast, and mammalian cells.
All reactions yielded fusion proteins of the appropriate molecular weight with yields
ranging from approximately 30-85%. (Figure 7.4.6a,b) Particularly important was the
successful ligation of whole antibodies without disruption of the associations between
their heavy and light chains or constant domains, and the fusion of multiple triglycine
reactants to substrates with multiple LPETG motifs-most notably the fusion of 3 whole
IgG to form a covalently bonded molecule composed of 12 individual protein domains
(Figure 7.4.6a,c). These results demonstrate the fusion of complex disulfide stabilized
protein domains, and coupled with the numerous pairings tested, greatly expand the
practical applicability of sortase A-mediated protein-protein fusion from the original
method carried out under reducing conditions and reported by Mao et a17 .
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LPETGXn Proteins
A33-LPETG-His6 IgG-LC-LPETG-GS
W GGGSLPETGGSHHHHHH
LPETGGS 7  LPETGGS
Triglycine (GGG-X) Proteins
39I /Q
Fab
CGG&T.
IgG albumin
Figure 7.4.5: Structures of constructs used for fusion tests
To demonstrate the preserved function of sortase-assembled fusion proteins,
magnetic beads were coated with antigen and then incubated with reaction mixtures
containing IgG-based fusion proteins: A33 IgG fused to GFP, and CEA IgG fused to A33
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antigen. The protein fused to the IgG was then detected by flow cytometry either directly
due to inherent fluorescence (detection of GFP), or by incubation with a conformation-
specific antibody-fluorophore conjugate (detection of A33 antigen). In both cases, high
signal intensity was observed, and signal was decreased in the presence of specific
competitor (Figure 7.4.6d,e), indicating that the conformation and functionality of both
fusion partners remained intact following sortassembly.
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Figure 7.4.6: Sortassembled products and functional testing. Nonreduced gel (a) and
reduced western blot (b) demonstrating the shift in molecular weight of an IgG light
chain-LPETGXn following fusion with 5 different triglycine partners. (c) Gel
demonstrating shift of A33 antigen-LPETGXn following fusion with 5 different
triglycine partners. Fusion products are marked with an asterisk. (d,e) Functional tests
of A33 IgG fused to GFP (d), and CEA IgG fused to A33 antigen (e). Blue trace
represents reaction mix, remaining traces represent bare beads, reaction mix without
sortase enzyme, and reaction mix with competitor IgG.
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7.5 Discussion
Post-translational protein fusion allows native expression of the individual fusion
partners-permitting expression of each domain in the optimum host, as well as allowing
modular pairing and assembly of component domains after expression-effectively
circumventing the diversity-limiting cloning steps of tandem genetic fusion. Alternative
solutions, including native chemical ligationi, intein and enzyme based strategies2 3 , and
residue specific chemistries relying on cysteines or unnatural amino acids4 tend to be
technically challenging, residue rather than site specific, or necessitate the inclusion of
whole additional protein domains to mediate fusion.
Previous reports reveal the broad applicability of sortase A catalyzed addition
reactions, and motivated this study of its use in producing complex fusion proteins. We
have described tractable in vitro conditions for the site-specific assembly of diverse,
multi-functional fusion proteins, requiring only 2 short peptide tags: a C-terminal
LPETGXn tag on one partner, and a complementary N-terminal triglycine (GGG) motif
on the other domain. These domains are small and generally unobtrusive to protein
production, yet allow site and stoichiometric control of the fusion reaction. Furthermore,
a suite of proteins may be expressed with these tags allowing for modular pairing of
diverse domains without additional molecular cloning effort, after being expressed a
single time.
By decoupling protein expression and fusion, and allowing native amide bonds to
be formed through inclusion of short peptide tags with site and stoichiometric control,
sortassembly promises to increase the diversity and ease of producing fusion proteins.
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